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The stereoselective formation of carbon-carbon bonds through the process of conjugate 
addition has proven to be a very important methodology in synthetic organic chemistry. In this 
context, oxadiazinones are chiral auxiliaries that have been applied in the asymmetric aldol 
addition reaction to synthesize valuable synthetic fragments such as the aldol side chain of the 
multi-drug resistance medicinal agent, hapalosin. This thesis describes efforts that were directed 
towards employing oxadiazinones as chiral scaffolds for the process of asymmetric conjugate 
addition with the ultimate objective of using this methodology in the preparation of medicinal 
agents such as Tolterodine. Preliminary efforts focused on using an N4-p-methoxybenzyl 
substituted oxadiazinone to achieve these goals. This oxadiazinone was acylated with trans-
cinnamic acid via the Steglich reaction with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and catalytic N,N-dimethylamino pyridine (DMAP). This substrate was then reacted with 
a Normant reagent, a mixture of the Grignard reagent, methylmagnesium bromide and copper (I) 
bromide-dimethylsulfide complex. The diastereoselectivity of the conjugate addition product was 
determined by analysis of the 500 MHz 1H NMR spectrum to be no greater than 3:1, a value 
unsuitable for meaningful asymmetric synthesis. This observation was in contrast to higher 
stereoselectivities observed in the asymmetric aldol reaction with Ephedra based oxadiazinones 
 
 
where ratios of 95:5 are commonly observed. To resolve this issue, a new series of 
oxadiazinones were designed, namely N4-isopropyloxadiazinone and N4-p-
diphenylmethyloxadiazinone. The observed diastereoselectivity of the asymmetric conjugate 
addition for the N4-isopropyloxadiazinone was lower. This reinforced the idea that the 
diastereoselectivity was being influenced by the conformational dynamics of the ring system and 
not just the N4-substituent. This thesis will describe the chemistry that has been accomplished to 
this point and make projections for future efforts in the synthesis of the medicinally valuable 
target compound, tolterodine (Detrol).    
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CHAPTER I: INTRODUCTION 
 
The term chirality comes from the Greek word “kheir-, hand” which implies 
“handedness”.1 Chiral molecules have the ability to exist in right- and left-hand forms and are 
categorized under a broad class of isomers known as stereoisomers. Stereoisomers are molecules 
with the same molecular and structural formulae but differ in the spatial arrangement of the 
atoms. This isomerism is a result of the presence of an atom, often a carbon atom, in the 
molecule, that is connected to four unique substituents. Such atoms are called chiral centers or 
stereocenters. If two stereoisomeric molecules are mirror images of each other and are not 
superimposable, they are referred to as enantiomers. However, if the stereoisomeric molecules 
cannot be related by a mirror plane, they are known as diastereomers. Enantiomers and 
diastereomers have major differences. While enantiomers may have one or more chiral centers, 
diastereomers that possess chirality must have at least two chiral centers. In addition, although 
enantiomers rotate plane polarized light in equal magnitude but opposite directions, they exhibit 
the same physical and chemical properties. In contrast, diastereomers usually differ in their 
physical and chemical properties, a characteristic exploited in this thesis project. Because 
enantiomers have identical enthalpies and entropies from when they arise from chemical 
reactions, they are usually obtained in equal amounts and this mixture is called a “racemic 
mixture”.2 Based on how the four unique substituents are arranged in space around the chiral 
centers of each enantiomer, they are described as either R-isomer or S-isomer.  
The importance of selectively synthesizing one enantiomer over the other in a 
biologically active molecule cannot be overemphasized. Due to identical composition and 
functional groups, enantiomers may exhibit similar chemical and physical properties, yet, they 
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may differ in their medicinal efficacy in biological environments.3 This is directly linked with 
the ability of naturally occurring  biomolecules such as enzymes to discriminate between 
different enantiomers due to the intrinsic chirality of enzymes.4 In fact, most biomolecules that 
make up our body systems are chiral in nature (Figure 1).5 For instance, proteins are composed 
of α-amino acids, most of which are chiral in nature. These biomolecules make up receptors in 
the human body and these receptors could be highly stereoselective. 
 
Figure 1. Chirality and biomolecules. 
 
 
As a result, a particular enantiomeric molecule may strongly interact with a biological 
receptor while the other enantiomer may only have a weak interaction (Figure 2).6 The 
implication of this is that one enantiomer of a drug may be effective in treating a certain disease 
while the other enantiomer may be weakly therapeutic, inactive, or toxic. In such cases, the 
active enantiomer is known as a eutomer while the inactive enantiomer is known as a distomer. 
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Figure 2. Enantioselectivity of biological receptors. 
 
 
There are numerous examples of drugs that fall into this category (Figure 3); Albuterol is 
a block buster drug that is sold as a racemic mixture and used in anti-asthmatic inhalant. The (R)-
isomer is the major active ingredient of the drug while the (S)-Albuterol (1) is significantly less 
effective.7 Another example is an antidepressant drug sold under the trade name Zoloft (2) which 
belongs to a group of compounds known as the aminotetralins.8 The  (1R,4S)-enantiomer of 
Zoloft is the eutomer while the (1S,4R)-enantiomer has no activity against depression. In the 
same vein, (R)-penicillamine (3) is an antidote against metal poisoning while the opposite 
enantiomer is capable of causing total blindness.9 
 
Figure 3. Examples of eutomers (pharmacologically active enantiomers). 
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The fact that stereochemistry has a direct influence on the potency and sometimes, on the 
toxicity of the drugs,10 makes it important to consider the pharmacological effects of drugs in 
their two enantiomerically pure forms and as the racemic mixture. Consequently, the topic under 
discussion possesses high relevance in the pharmaceutical industry.    
Of all the cases of different side effects associated with the use of a drug as a racemic 
mixture ever reported, the most catastrophic of all is the thalidomide incident which occurred in 
the 1950s.11,12  Thalidomide (Figure 4) was a drug synthesized by a German pharmaceutical 
company known as Grünenthal Chemie in the 1950s. The drug was primarily distributed in 
Germany, Australia and Canada and was reported further distributed in more than 46 countries. 
The drug was administered to pregnant women with the sole aim of suppressing morning 
sickness.  It was ultimately discovered that those women who took thalidomide gave birth to 
deformed babies. Some babies were born with deformed arms and legs, some had deformed 
faces while some were too deformed to survive. About 2,000 deaths were recorded as a result of 
thalidomide and more than 10,000 deformed babies were reported.13  
 
Figure 4. The (S)-enantiomer (left) and the (R)-enantiomer of thalidomide. 
 
4a 4b 
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Nearly two decades after the onset of the thalidomide tragedy, researchers unraveled the 
mystery behind the incident.14a It was noted that the drug was sold as a racemic mixture of the 
(R)- and (S)-enantiomers as illustrated in Figure 4. The (R)-enantiomer (4b) has a sedative effect, 
relieving pregnant women of morning sickness while the (S)-enantiomer (4a) is a teratogen that 
interferes with fetal development. It was initially thought that the individual enantiomers could 
be separated so that there could still be therapeutic value for pregnant women dealing with 
morning sickness. Unfortunately, the (R)- and (S)-enantiomers interconvert in vivo thereby 
making the separation of enantiomers of no practical value (Scheme 1).14b  
 
Scheme 1. Racemization of Thalidomide in a biological environment.   
 
 
A study conducted in Brazil in 2016 and reported in the European Journal of Medical 
Genetics showed that thalidomide children are still being born yearly.14c Even though the World 
Health Organization (WHO) initially withdrew the drug from the market, its sale was later 
allowed due to its effectiveness in treating other diseases such as leprosy. It was proposed by the 
authors that the availability of thalidomide to pregnant women in Brazil trying to manage leprosy 
symptoms led to the birth of numerous deformed children in 2016.  
Thalidomide is a paramount example of the importance of molecular chirality in 
pharmaceutical agents. Even though there is no value in isolating the individual enantiomers, it is 
6 
 
an important lesson in the differing levels of biological activity of enantiomers. Reactions that 
are designed to selectively form one enantiomer over the other are collectively known as 
stereoselective reactions. Such reactions can be further described as being asymmetric reactions 
or asymmetric syntheses.  
Asymmetric synthesis involves inducing chirality into a substrate, preferentially forming 
one stereoisomer over the other; this process is formally known as asymmetric induction. One 
way of achieving asymmetric synthesis is through the use of compounds known as chiral 
auxiliaries. Chiral auxiliaries are organic compounds with pre-existing fixed chiral centers. They 
therefore assist in preferentially establishing the stereochemistry of a new chiral center in 
molecules. As such, the usage of chiral auxiliaries has been proven to be an effective tool in 
controlling asymmetry in a wide variety of reactions.15 Beyond this, the stereoselective formation 
of carbon-carbon bonds through the process of asymmetric conjugate addition has proven to be a 
very important methodology in synthetic organic chemistry.16-18 The use of chiral auxiliaries to 
guide the stereoselective bond formation has continued to be a reliable methodology for 
obtaining products in high diastereoselectivity (Figure 5). 
Koga’s lactam (6) was one of the first chiral auxiliaries successfully used in the process 
of asymmetric conjugate addition.19 The diastereoselectivities for this process were high, but the 
chiral auxiliary did not offer the practicality of ease of preparation. This auxiliary would be 
followed by the more successful application of Oppolzer’s sultam (7).20-24 The sultam is based on 
the D-camphor template and has proven to be applicable in a variety of conjugate addition 
applications. Another chiral auxiliary that has been employed for the process of asymmetric 
conjugate addition is Chiacchio and Romeo’s bicyclic sultam (8).25 While not as employed to the 
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same degree as Oppolzer’s sultam, the bicyclic sultam template was still successful in its 
applications.  
 
Figure 5. Chiral auxiliaries for diastereoselective conjugate addition reactions.  
 
 
Badía and coworkers26-29 developed a more practical chiral auxiliary based on using 
Myers’(1S,2S)-pseudoephedrine (9)30a,b template as a chiral template for asymmetric conjugate 
addition. While this chiral template has proven to be very useful, the dominant chiral auxiliary 
that has been employed in chiral auxiliary mediated asymmetric conjugate additions is the 
Evans’ oxazolidinone (10).31-38 The Evans’ auxiliary has proven to be the most versatile of all of 
the auxiliaries presented here. While catalytic asymmetric conjugate addition methods are 
continuing to increase in their applications, the Evans’ oxazolidinone remains as a viable option 
to achieve asymmetric synthetic ends.  In this context, in 2019, Ortiz and coworkers39,40 were 
able to synthesize a series of gamma-amino acids by this methodology (Scheme 2). 
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Scheme 2. The Ortiz asymmetric application of the Evans’ oxazolidinone. 
 
 
Also, Takayama and coworkers employed the Evans’ oxazolidinone in the synthesis of 
the Lycopodium alkaloid Lycopoclavamine-A via an asymmetric conjugate addition (Scheme 
3).41 
 
Scheme 3. The Takayama asymmetric application of the Evans’ oxazolidinone. 
 
 
 The most commonly used of the Evans’ chiral auxiliary are derived from naturally 
occurring compounds such as L-phenylalanine (18) and L-valine (20) and some unnatural α-
amino acids such as L-phenylglycine (19), L-tert-leucine (21) and modified L-serine (22) (Figure 
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6). The use of the Evans’ chiral auxiliary in asymmetric synthesis follows a general pathway of 
acylation and conjugate addition reactions (Scheme 4).31-36 For the oxazolidinones, the C4-
position is the stereochemical controlling element. 
 
Figure 6. Various amino acids source for the Evans’ oxazolidinones formation.  
 
 
Scheme 4. General pathway for asymmetric synthesis using the Evans’ oxazolidinones. 
Stereochemical control element
 
10 
 
Several researchers have carried out structural modifications on the Evans’ five-
membered-ring oxazolidinone by varying the substituent at the C4-position with the goal of 
achieving an improved diastereoselectivities (Figure 7).42-48  
 
Figure 7. Structural modifications to the Evans’ chiral auxiliary.  
 
 
Some of the structural modifications include the introduction of diphenyl methyl group 
by Sibi and coworkers (29), introduction of a polymer backbone by Abell et al. (31), introduction 
of sulfur analog by Crimmins et al. (32), conversion into a bicyclic structure by de Parrodi et al. 
(33) and so on. However, the original Evans’ oxazolidinone developed in the early 1980s (18) 
has withstood the test of time as it was recently used by Williams and coworkers in their 
synthesis of Baulamycin A recently published in the Journal of Organic Chemistry in January 
2020.49 
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The successful application of the Evans’ auxiliary in numerous conjugate addition 
applications served as the impetus for the proposed research described herein. There was an 
interest in conducting asymmetric conjugate addition reactions, but it was decided to take a 
different route other than modifying the classical oxazolidinones. This led us to a six-membered 
ring class of compounds known as the oxadiazinones (34).  In this context, oxadiazinones are 
chiral auxiliaries that are structurally related to the Evans’ oxazolidinone as aza-homologs. 
Oxadiazinones represent a class of heterocycles that were first prepared by the Dow Chemical 
Company in a research program led by Trepanier and coworkers50,51 in the 1960s. The goal of 
synthesizing the oxadiazinones by Dow was not for it to be used as a chiral auxiliary. Rather, it 
was meant to serve as a therapeutic agent. It was tested against Parkinson disease and some 
cardiovascular diseases, of which in both cases, it was found ineffective. As a result, literature 
references concerning the Ephedra based oxadiazinones became sparse from the chemical 
literature for about two decades. Not until the late 1990s when it was employed by Husson and 
coworkers in diastereoselective alkylations (35)52 and asymmetric dipolar cycloadditions (36)53,54 
(Figure 8).   
 
Figure 8.  Examples of chiral oxadiazinones.  
 
 
Our research group first utilized the oxadiazinones as chiral auxiliaries in the early 2000s 
where they were applied as chiral auxiliaries in the asymmetric aldol addition reaction (Scheme 
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5).55,56 The success of the asymmetric induction in the oxadiazinone mediated aldol reaction is 
believed to be due to the stereogenic N4-nitrogen which serves at the stereochemical control 
element guiding the reaction.   
 
Scheme 5. Oxadiazinones in the asymmetric aldol addition reaction. 
 
 
 This is partially based on the fact that the observed diastereoselectivities for the asymmetric 
aldol reaction ranges from 3:1 to 99:1 when the N4-substituent is a methyl group, and ranges 
from 10:1 to 99:1 when the N4-substituent is a much larger isopropyl group.  The conformation 
and the configuration of the N4-nitrogen is a result of chiral relay where stereochemical 
information is relayed from the C5 and C6 positions of the oxadiazinone ring system.  An X-ray 
crystal structure for aldol adduct (Figure 9) was obtained and serves to suggest that it is the N4-
position that directs the stereochemistry of the aldol process. 
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Figure 9. Chiral relay in oxadiazinone mediated asymmetric aldol reactions: X-ray crystal 
structure. 
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 The high diastereoselectivity achieved with the oxadiazinones in the asymmetric aldol 
addition reaction suggested that this chiral auxiliary could be employed as well as chiral 
templates in asymmetric conjugate addition reactions. Thus, the proposed research would follow 
the same reaction pathway as the oxazolidinones of Evans’ in the use of oxadiazinones as chiral 
auxiliaries (Scheme 6). Should the oxadiazinone-guided asymmetric conjugate addition reaction 
be successful, then it will be employed as a chiral template in the synthesis of the medicinal 
agent tolterodine. 
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Scheme 6. General pathway of conjugate addition reaction with the oxazolidinone and proposed 
conjugate addition pathway with the oxadiazinones. 
 
 
 
 Tolterodine (45) (Figure 10) is a medicinal agent distributed under the trade name Detrol 
and sold by Pfizer, Inc. It belongs to a class of drugs known as antispasmodics used in 
countering involuntary contraction of muscles. Tolterodine is specifically used in the treatment 
of overactive bladder. It helps in relaxing the muscles in the bladder and thereby improves the 
patient’s ability to control urination. It helps in reducing urine leakage, feelings of frequent 
urination and ultimately prevent frequent bathroom visits.57,58 
 
Figure 10. Tolterodine 
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It is proposed that tolterodine will be synthesized following the general pathway of 
acylation using the Steglich reaction (Figure 11). This will involve the acylation of the 
heterocycle (34) with  trans-cinnamic acid to obtain the acylated oxadiazinone (43) followed by 
conjugate addition reaction with a Normant reagent (cupper bromide dimethyl sulfide and 2-
benzyloxy-5-methyl phenylmagnesium bromide, 46) to create the conjugate addition product 
(47) with a new chiral center. This will then be subjected to hydrolysis to cleave off the chiral 
auxiliary and obtained the carboxylic acid (48). The carboxylic acid can then be taken through 
the Steglich reaction with diisopropylamine to obtain the intermediate 49 which will then be 
reduced and deprotected to obtain the tolterodine (45).  
 
Scheme 7. Proposed pathway for tolterodine synthesis using the oxadiazinones as chiral 
templates. 
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In summary, this chapter has presented the importance of molecular chirality in bioactive 
molecules, and why it is important that medicinal agents are carefully evaluated for the 
properties of their enantiomers and racemic mixtures. Oxazolidinones have also been discussed 
as the mostly used chiral auxiliary in asymmetric synthesis to date.  Likewise, the use of 
oxadiazinones as structurally novel chiral auxiliaries in the asymmetric aldol addition reaction 
have been discussed. The goal of this research is to apply these oxadiazinones in the synthesis of 
the medicinal agent tolterodine (Detrol), through asymmetric conjugate addition reaction.   
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CHAPTER II: OXADIAZINONES AS CHIRAL AUXILIARIES IN ASYMMETRIC 
CONJUGATE ADDITION REACTIONS 
 
Introduction 
 
As stated in Chapter I, the oxadiazinones have proven to be effective tools for conducting 
chiral auxiliary-directed asymmetric aldol addition reactions. The oxadiazinones that have been 
employed have relied primarily on the N4-substituent as the stereochemical control element 
leading to the observed diastereoselection in the asymmetric aldol addition reaction. This chapter 
explores the use of the chiral oxadiazinones in the process of asymmetric conjugate addition 
reactions (Figure 11). The oxadiazinones that will be presented in this chapter will also feature 
this N4-substituent as a key element of variation in the pursuit of the best possible 
diastereoselectivities (Figure 11).  
 
Figure 11.  Proposed oxadiazinone mediated asymmetric conjugate addition pathway. 
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Results and Discussion 
Ephedrine based oxadiazinones, synthesis, acylation and asymmetric conjugate addition 
 
The conjugate addition project began with the same ephedrine based oxadiazinone that 
launched the asymmetric aldol addition project that was described in Chapter 1. The (1R,2S)-
ephedrine based oxadiazinone (34) was synthesized in a three-step reaction: N-nitrosation, 
lithium aluminum hydride reduction, and cyclization (Scheme 8). The (1R,2S)-ephedrine (52) 
starting material was reacted with sodium nitrite (NaNO2) in the presence of aqueous 
hydrochloric acid (HCl, 3M) and tetrahydrofuran (THF) to give the N-nitrosamine target (53a 
and 53b) as a mixture of E- and Z-diastereomers in a yield of 95%. The (1R,2S)-ephedrine based 
N-nitrosamine thus obtained was reacted with the reducing agent lithium aluminum hydride 
(LiAlH4) using THF as solvent. This afforded the (1R,2S)-ephedrine based hydrazine (54) in a 
93% yield. The hydrazine product was immediately taken through a cyclization reaction with 
carbonyldiimidazole (CDI) (55) in the presence of THF to give the target (1R,2S)-ephedrine 
based oxadiazinone (34) as a white solid in a 74% yield.  
 
Scheme 8. Synthesis of (1R,2S)-ephedrine based oxadiazinone 25. 
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The mechanisms of these reactions are shown in Schemes 9-11. The N-nitrosation 
follows the standard pathway for the N-nitrosation of a secondary amine in which nitrous acid is 
generated in situ and reacted with the ephedrine substrate (Scheme 9). The lithium aluminum 
hydride reduction involves the formation of hydrogen gas as the initial step with subsequent 
attack of the hydride on the nitrosamine functional group (Scheme 10). The process ultimately 
yielded the desired ephedrine-based hydrazine. The hydrazine in turn reacted with 
carbonyldiimidazole through a series of nucleophilic addition/elimination pathways to form the 
target ephedrine based oxadiazinone.59  
 
Scheme 9. The N-nitrosation reaction mechanism for the formation of compound 53. 
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Scheme 10. The lithium aluminum hydride reduction reaction mechanism for the formation of 
compound 54. 
 
Scheme 11. The cyclization reaction mechanism for the formation of compound 34. 
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The (1R,2S)-ephedrine based oxadiazinone (34) thus obtained was acylated following the 
method of Steglich and coworkers,60 in which the heterocycle was reacted with trans-cinnamic 
acid (56) in the presence of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (57), and 4-
(dimethylamino)pyridine (DMAP) catalyst (58) to afford the N3-cinnamoyloxadiazinone (43) in 
a 71% yield after chromatography purification (Scheme 12). With this material in hand, the 
asymmetric conjugate addition reaction was carried out using the Normant conditions.61,62 Thus, 
the acylated oxadiazinone (43) was treated with a mixture of methylmagnesium bromide and 
copper bromide-dimethylsulfide complex to yield the conjugate addition product in a 65% 
isolated chemical yield after chromatographic purification. The reaction mechanisms for the 
acylation and conjugate addition reactions are shown in Schemes 13 and 14, respectively. 
 
Scheme 12. Acylation and conjugate addition with the (1R,2S)-ephedrine based oxadiazinone for 
the formation of compound 59. 
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Scheme 13. Mechanism of reaction for the oxadiazinone acylation for the formation of 
compound 43. 
 
 
Scheme 14. Mechanism of reaction for the asymmetric conjugate addition reactions63,64 leading 
to the formation of compound 59. 
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This reaction generated a mixture of diastereomeric products (59a and 59b) in a ratio of 
5.1:1 in favor of the major diastereomer as determined by 500 MHz 1H NMR spectroscopy 
(Figure 12). The major diastereomer was tentatively assigned as the (R)-diastereomer (59a) 
based on the stereochemical orientation of the N4-methyl group. 
 
Figure 12. 500 MHz 1H NMR spectrum of the conjugate addition product of (1R,2S)-ephedrine 
based oxadiazinone.  
 
 
 
 
Predicted S-isomer 
Predicted R-isomer 
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Stereochemistry determination of (1R,2S)-ephedrine conjugate addition product through 
classical resolution 
 
The stereochemistry of the diastereomeric products of the conjugate addition reaction 
with the (1R,2S)-ephedrine based oxadiazinone was determined through the use of classical 
resolution (Scheme 15).65,66 This was accomplished by reacting 5.24 grams of racemic mixture 
of a commercially sourced 3-phenylbutyric acid (60a and 60b) with an enantiomerically pure 
chiral amine, (S)-(-)-phenylethylamine (61).  This reaction generated a mixture of diastereomeric 
carboxylate salts (62a and 62b). The generated salts, being diastereomers, differ in their physical 
and chemical properties. Hence, one of the salts was very soluble in ethanol-water solution while 
the other salt readily formed fine long needles of white crystals. The crystals were recovered by 
vacuum filtration and subjected to a second recrystallization using ethanol and water. 
The salt (62b) obtained from this process was subjected to extraction using aqueous 
hydrochloric acid (1M) and diethyl ether which aided the recovery of the single diastereomer of 
the phenyl butyric acid in a 48% isolated recovered yield. (Scheme 16). The optical rotation of 
the recovered acid was determined by polarimetric analysis to be [α]D = +43o (75% ee). From the 
known compound (60a and 60b), the (R)-isomer has a known optical rotation of -57o while the 
S-isomer has an optical rotation of +57o. This suggests that the recovered carboxylic acid was the 
S-enantiomer of the butyric acid and that the salt that initially came out of the ethanol-water 
solution was the (S-amine, S-carboxylic acid)-diastereomer (62b). 
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Scheme 15. Stereochemistry determination by classical resolution. 
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Scheme 16. Stereochemistry determination: polarimetric analysis.  
 
 
 
The (S)-(+)-3-phenylbutyric acid (60a) obtained from the classical resolution was 
acylated with the (1R,2S)-ephedrine based oxadiazinone (34) using the Steglich reaction 
conditions (Scheme 17). The acylated product (63) obtained was then analyzed by 500 MHz 1H 
NMR spectroscopy. The obtained spectrum (Figure 13) was then compared with the 500 MHz 
1H NMR spectrum obtained from the initial ephedrine based oxadiazinone directed conjugate 
addition reaction (Figure 14). 
 
Scheme 17. Stereochemistry determination: Steglich reaction with the recovered butyric acid.  
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Figure 13. 500 MHz 1H NMR spectrum of the product of Steglich reaction between the (1R,2S)-
ephedrine based oxadiazinone and (S)-(+)-3-phenylbutyric acid (60a). 
 
 
Figure 14. 500 MHz 1H NMR spectrum of the conjugate addition product of (1R,2S)-ephedrine 
based oxadiazinone.  
 
 
From the results obtained from the classical resolution, it became clear that the (S)-isomer 
was the major isomer! This was contrary to the initial prediction that the (R)-isomer was the 
major isomer. It then became essential to consider what could be the reason behind the S-
isomer’s domination in this reaction. 
 
 
 
 
R-isomer 
S-isomer 
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Rationale to why the (S)-diastereomer was observed as the major isomer 
 
Following the classical resolution results, a rationalization of the stereochemical outcome 
had to be made as the observed result was diametrically opposed to the predicted result. It is 
proposed that if the N3-acyl side chain is held in place as seen (65), then the (R)-isomer is 
expected to be the dominant isomer. However, if there is a flexibility around the α-carbon, such 
that the acyl side chain is rotated downward as shown (64), then the (S)-isomer becomes the 
dominant isomer. There may be other potential transition states that give rise to the observed 
stereochemical outcome. Ultimately, the diastereoselectivity observed for this system (5.1:1) is 
below the desired diastereoselectivity ratio desired for this work. As such, another family of the 
Ephedra alkaloid, namely (1S,2S)-pseudoephedrine, was considered. 
 
Scheme 18. Rationale for the observed stereoselectivity in the ephedrine-based system.  
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Pseudoephedrine based oxadiazinone, synthesis, acylation and asymmetric conjugate addition 
 
In a bid to improve the diastereoselectivity of the oxadiazinones in asymmetric conjugate 
addition reaction, the (1S,2S)-pseudoephedrine based oxadiazinone (70) was also examined.  
This oxadiazinone was synthesized by reacting the (1S,2S)-pseudoephedrine substrate (67) with 
sodium nitrite in the presence of hydrochloric acid (3M) and tetrahydrofuran (THF) to give the 
N-nitrosamine diastereomers (68a and 68b) in near quantitative yield of 97%. The N-nitrosamine 
product was then reacted with LiAlH4 in the presence of THF to afford the hydrazine (69) with a 
near quantitative yield of 99%. The hydrazine was, in turn, reacted with cabonyldiimidazole to 
give the (1S,2S)-pseudoephedrine based heterocycle (70) in a 74% yield (Scheme 19).  
 
Scheme 19. Synthesis of the (1S,2S)-pseudoephedrine based oxadiazinone 70.  
 
 
With the pseudoephedrine heterocycle (70) in hand, a Steglich reaction (Scheme 20) was 
conducted in which trans-cinnamic acid was coupled with the heterocycle using the coupling 
agent EDC and DMAP catalyst to afford the corresponding N3-trans-cinnamoyloxadiazinone 
(71) in a 59% yield after chromatography purification.  
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Scheme 20. Acylation of the (1S,2S)-pseudoephedrine based oxadiazinone. 
 
 
The purified N3-trans-cinnamoyloxadiazinone (71) was then subjected to Normant-
Grignard addition reaction (Scheme 21) to yield the corresponding N3-(3-methyl 
hydrocinnamoyl) oxadiazinone as a mixture of diastereomers (72a and 72b) in a 79% yield after 
chromatography.  
 
Scheme 21. Asymmetric conjugation addition with the (1S,2S)-pseudoephedrine-N3-
cinnamoyloxadiaxinone. 
 
  
The diastereoselection ratio was determined by the use of 500 MHz 1H NMR 
spectroscopy (Figure 15) to be 3.4:1, with the R-isomer (72a) assigned as the major diastereomer 
tentatively.  
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Figure 15. 500 MHz 1H NMR spectrum of the conjugate addition product of (1S,2S)-
pseudoephedrine system. 
 
 
Apart from lower diastereoselectivity observed relative to the (1R,2S)-ephedrine system, 
there was also a line broadening of one of the diagnostic peaks in the 500 MHz 1H NMR 
spectrum of the pseudoephedrine based oxadiazinone directed conjugate addition products (72a, 
b) (Figure 14). This led to a follow-up investigation of the starting material (71) for this reaction. 
A 13C NMR spectral analysis was carried out on the acylated starting material for both the 
(1R,2S)-ephedrine based oxadiazinone (43) and the (1S,2S)-pseudoephedrine based oxadiazinone 
(71). The spectra obtained for the two compounds (Figure 16), suggested that the ephedrine-
based compound (43) is conformationally rigid while the pseudoephedrine-based system (71) in 
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conformationally flexible, which could be the reason for the lower diastereoselectivity observed 
in relation to the ephedrine-based system. 
 
Figure 16. 125 MHz 13C NMR spectra comparing the conformational rigidity of the ephedrine 
based oxadiazinone (43, top) and the pseudoephedrine based oxadiazinone (71, bottom) systems. 
 
 
As a result of the low diastereoselectivity and the conformational flexibilities exhibited 
by the pseudoephedrine-based system, another member of the Ephedra family, the (1R,2S)-
norephedrine based N4-para-methoxybenzyloxadiazinone was also considered. It was projected 
that the larger group at the N4-position would significantly improve the diastereoselectivity of 
the oxadiazinone. 
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Norephedrine based oxadiazinone, synthesis, acylation and asymmetric conjugate addition 
 
In pursuit of an improved diastereoselectivity in the asymmetric conjugate addition 
synthesis, a norephedrine based oxadiazinone (73) was also employed (Figure 17). In this case, 
the N4-substituent (stereochemical control element) would be a para-methoxybenzyl (PMB) 
group, a group that was believed would aid in improving diastereoselectivity due to its larger 
steric demand compared to the N4-methyl group. This para-methoxy-benzyl- substituted 
oxadiazinone was synthesized from the (1R,2S)-norephedrine precursor (74) (Figure 18).  
 
Figure 17. The Ephedra based oxadiazinones.  
 
 
Figure 18. The Ephedra alkaloids as the key starting materials for the formation of the 
oxadiazinones. 
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The synthesis follows similar reaction pathway as the ephedrine and pseudoephedrine-
based systems (Scheme 22). However, prior to the N-nitrosation reaction, the (1R,2S)-
norephedrine was subjected to reductive amination with para-methoxybenzaldehyde (74) in the 
presence of ethanol absolute to introduce the -PMB group. The reaction was later brought to 
completion through the addition of sodium borohydride (NaBH4) as shown the reaction 
mechanism (Scheme 23) leading to the formation of the amino alcohol (75).  Without further 
purification, the α-amino alcohol was immediately converted to the corresponding N-nitrosamine 
(76) in a 95% yield through reaction with sodium nitrite in the presence of aqueous HCl (3M) 
and THF. With the N-nitrosamine in hand, a lithium aluminum hydride (LiAlH4) reduction was 
carried out using THF as the solvent. This led to the isolation of the corresponding hydrazine 
(77) in a 90% yield. The hydrazine was then reacted with carbonyldiimidazole using THF as 
solvent. This yielded the (1R,2S)-norephedrine based N4-p-methoxybenzyl oxadiazinone (73) in 
a 47% yield. 
 
Scheme 22. Synthesis of the (1R,2S)-norephedrine-N4-p-methoxybenzyl oxadiazinone, 73 
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Scheme 23. Reductive amination reaction mechanism for the formation of N4-p-methoxybenzyl 
amino alcohol, 75. 
 
 
 
To determine if the steric volume of the incoming group would have an impact on the 
diastereoselectivities of the conjugate addition reactions, the para-methoxybenzyl oxadiazinone 
(73) was taken through two different acylation pathways (Scheme 24). In the first reaction 
(Scheme 24a), the heterocycle was acylated with trans-cinnamic acid using the Steglich reaction 
conditions to give the (1R,2S)-norephedrine based N4-p-methoxybenzyl-N3-cinnamoyl 
oxadiazinone (78) in an 80% yield. In this case, methyl magnesium bromide (CH3MgBr) would 
be employed as the Grignard reagent for the conjugate addition reaction. In the second reaction 
pathway (Scheme 24b), on the other hand, the heterocycle was acylated with trans-
crotonylchloride (79) in the presence of sodium hydride (NaH) base and THF to yield the 
(1R,2S)-norephedrine based N4-p-methoxybenzyl-N3-crotonyl oxadiazinone (80) in a 51% yield. 
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Here, the conjugate addition reaction would be conducted using phenyl magnesium bromide 
(PhMgBr) as the Grignard reagent. 
 
Scheme 24. Acylation reactions with the (1R,2S)-norephedrine based oxadiazinone using (a) 
trans cinnamic acid and (b) trans-crotonyl chloride, for the formation of the acylated products 78 
and 80.  
 
 
With the acylated  products in hand, the (1R,2S)-norephedrine based N4-p-
methoxybenzyl-N3-cinnamoyl oxadiazinone (78) was taken through asymmetric conjugate 
addition reaction (Scheme 25) using copper bromide dimethyl sulfide (CuBr S(CH3)2) and 
methyl magnesium bromide (CH3MgBr) (the Normant reagent) to give the conjugate addition 
product (81) as a mixture of diastereomers (81a & 81b) in a 62% yield. In this case, a methyl 
group was added to the unsaturated side chain to create a new chiral center. 
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Scheme 25. Asymmetric conjugation addition in the formation of compound 81. 
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Scheme 26. Asymmetric conjugation addition in the formation of compound 82. 
  
 
Likewise, the (1R,2S)-norephedrine-N4-p-methoxybenzyl-N3-crotonyloxadiazinone (80) 
was subjected to an asymmetric conjugate addition reaction (Scheme 26) using copper bromide 
dimethyl sulfide (CuBr S(CH3)2)  and phenyl magnesium bromide (PhMgBr) to give the 
conjugate addition product (82) as a mixture of diastereomers (82a and 82b) in a 52% yield. 
Here, the incoming group added to the unsaturated side chain was the more sterically demanding 
phenyl group. Both conjugate addition products (81 and 82) were analyzed by 500 MHz proton 
NMR spectroscopy. 
The (1R,2S)-norephedrine-N4-p-methoxybenzyl-N3-(3-phenylbutanoyl) (81) gave a 
diastereomeric ratio of 2.9:1 in favor of the major diastereomer (Figure 19). The (1R,2S)-
norephedrine based N4-p-methoxybenzyl- N3-(3-phenylbutanoyl) (82) also gave a diastereomeric 
ratio of 2.9:1 in favor of the major diastereomer (Figure 20). This implies that the steric volume 
of the incoming group has no direct impact on the stereoselectivities of the asymmetric conjugate 
addition reactions.   
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Figure 19. 500 MHz 1H NMR spectrum of the (1R,2S)-norephedrine based N4-p-
methoxybenzyl-N3-(3-phenylbutanoyl) oxadiazinone (81).  
 
 
 
Figure 20. 500 MHz 1H NMR spectrum of the (1R,2S)-norephedrine based N4-p-
methoxybenzyl-N3-(3-phenylbutanoyl) oxadiazinone (82).  
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Based on the stereochemical orientation of the N4-p-methoxybenzyl group (the 
stereochemical control element), the (R)-isomer (81a) was assigned the major diastereomer in 
the case of the cinnamoyl system while the (S)-isomer (82a) was assigned the major 
diastereomer in the case of the crotonyl system. 
 
Stereochemistry determination of (1R,2S)-norephedrine conjugate addition product through 
hydrolysis 
 
To establish the stereochemical orientation of the major and minor isomers of the 
norephedrine system, the addition product (81) was subjected to oxidative hydrolysis using ceric 
ammonium nitrate (Ce(NH4)2(NO3)6  and acetonitrile (CH3CN) in an aqueous medium to recover 
the acyl side chain of the conjugate addition products (Scheme 27). 
 
Scheme 27. The norephedrine stereochemistry determination by hydrolysis and polarimetric 
analysis.  
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 The phenyl butyric acid side chain (84) was isolated from this reaction in a 22% yield 
after chromatography purification. The recovered acid was then taken through polarimetric 
analysis giving an optical rotation of +22o (39% ee), suggesting that the (S)-isomer is also the 
major isomer in this case, contrary to the predicted R-isomer.   
 
Rationale for the low diastereoselectivities and stereochemical orientation of the major isomer 
 
As stated earlier, just as in the case of the ephedrine based oxadiazinone (59), the major 
isomer for the norephedrine-based system turned out to be the (S)-isomer as against the (R)-
isomer which was predicted based on the stereochemical orientation of the N4-para-
methoxybenzyl group. To rationalize this observation, the acylated starting material (78) was 
analyzed by 125 MHz 13C NMR (Figure 21). The analysis suggested that the acylated starting 
material is conformationally rigid. This was evident in the distinct peaks present in the alkyl 
carbon region of the spectrum contrary to peaks distortions observed in this region in the 
pseudoephedrine-based system. 
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Figure 21. Investigation of conformational rigidity of the norephedrine based system by 125 
MHz 13C NMR.  
 
  
 
This observation suggested that the pyramidal inversion observed in the case of the 
pseudoephedrine (Figure 16) is not relevant in the case of this norephedrine-based oxadiazinone. 
The explanation that could possibly be given for the low diastereoselectivity observed for this 
system therefore, is a possible conformational flexibility of the acyl side chain in the molecule 
(Figure 22).  
 
78 78
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Figure 22. Rationale for the observed stereoselectivity in the norephedrine based system.  
  
 
 
In Figure 22 above, if the intermediate 78c was predominantly formed, the R-isomer 
(81a) would be the major isomer. On the other hand, if the intermediate 78d was predominantly 
formed, then the S-isomer (81b) would be expected to be the major isomer. However, there is a 
possibility of both intermediates competing with each other and forming in almost equal 
amounts. If this is the situation, then the observed low diastereoselectivity is unavoidable. 
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More efforts towards increasing the diastereoselectivity of the conjugate addition: The N4-para-
methoxybenzyloxadiazinone from L-phenyl alaninol, synthesis and application 
 
Following the attempts made to obtain high diastereoselectivities in the asymmetric 
conjugate additions from the Ephedra-based oxadiazinones, a new oxadiazinone, the N4-para-
methoxybenzyloxadiazin-2-one (89) was also considered (Scheme 28). In this new system, L-
phenylalaninol (85) was employed as the precursor for the oxadiazinone synthesis in place of the 
norephedrine (74). Based on the low diastereoselectivities obtained from the para-methoxybenzyl 
norephedrine-based oxadiazinone (73), a more sterically demanding group was envisioned as a 
good candidate to be considered as the stereochemical control element (N4-substituent) (Figure 
23). Unfortunately, the (1R,2S)-norephedrine could not be used to accomplish this purpose. 
 
Figure 23. Comparison between the norephedrine and the L-phenylalaninol based oxadiazinones.  
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This is because of the scarcity and high cost associated with this compound.67 As a result, 
L-phenylalaninol (85), a compound derived from the natural α-amino acid L-phenylalanine, was 
employed as an alternative precursor for the synthesis of the new oxadiazinones. Before 
proceeding to the isopropyl-substituted heterocycle, a derivative of the para-methoxybenzyl 
(PMB) substituted oxadiazinone (73), the L-phenylalaninol-based-N4-PMB oxadiazinone (89), 
was synthesized using the L-phenylalaninol starting material. The synthesis began with the 
reductive amination of the amino acid derivative L-phenylalaninol (85) with para-anisaldehyde 
in the presence of ethanol (100%) (Scheme 28).  
The reaction afforded the amino alcohol N4-para-methoxybenzyl L-phenyl alaninol (86) 
in a 78% yield. The N4-para-methoxybenzyl L-phenylalaninol product was then taken through 
N-nitrosation reaction using sodium nitrite, an aqueous solution of HCl (3M), and 
tetrahydrofuran which resulted in the target N-nitrosamine (89) in a 65% yield. Without further 
purification, the N-nitrosamine was subjected to LiAlH4 reduction in the presence of 
tetrahydrofuran to yield the target beta-hydroxy hydrazine (88) in a 31% yield. The hydrazine 
product thus obtained was then dissolved in tetrahydrofuran and subjected to a cyclization 
reaction via the coupling agent carbonyl diimidazole (55). This reaction afforded the N4-para-
methoxybenzyloxadiazin-2-one (89) in a 35% yield after chromatography purification. 
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Scheme 28. Synthesis of the L-phenylalanine based N4-para-methoxybenzyl-oxadiazin-2-one, 
89. 
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Acylation and asymmetric conjugate addition with L-phenylalaninol-N4-para-methoxybenzyl-
oxadiazinone 
 
The L-phenylalaninol based N4-para-methoxybenzyloxadiazinone (89) thus obtained was 
subjected to an acylation reaction (Scheme 29) using trans-cinnamic acid (56) in the presence of 
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) (57) coupling agent and 4-
dimethylaminopyridine (DMAP) catalyst (58). The L-phenylalaninol-N4-para-methoxybenzyl-
N3-cinnamoyl oxadiazinone (90) product obtained in this process was purified by column 
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chromatography in a 65:35, hexane: ethyl acetate solvent system, which resulted in a 71% yield 
of the target product. 
 
Scheme 29. Acylation of the L-phenylalanine based N4-para-methoxybenzyl-oxadiazinone, 89. 
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The pure N4-para-methoxybenzyl-N3-cinnamoyl oxadiazinone (90) obtained from the 
Steglich reaction above was analyzed by 500 MHz 1H NMR and 125 13C NMR spectroscopy. 
The analysis of these spectra revealed that some of the signals were significantly broadened 
which suggested that this compound is conformationally flexible. Nonetheless, for the sake of 
experimentation, the acylated product was subjected to an asymmetric conjugate addition 
reaction (Scheme 30).  
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Scheme 30: Asymmetric conjugation addition reaction with the N4-para-methoxybenzyl-N3-
cinnamoyl oxadiazinone 91. 
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The conjugate addition reaction was carried out in the presence of methyl magnesium 
bromide, copper bromide (Normant reagent), tetrahydrofuran (THF) and dimethyl sulfide 
(DMS). The corresponding N3-(3-phenylbutanoyl)- N4-para-methoxybenzyl oxadiazinone target 
was obtained and purified by flash column chromatography, leading to the isolation of the target 
molecule as a mixture of diastereomers (91a and 91b) in an unoptimized yield of 9.8%.  
From the analysis of the 500 MHz 1H NMR spectrum of the conjugate addition product, 
significant line broadening was observed in multiple signals.  This was indicative of 
conformational flexibility observed in the conjugate addition products. It was not possible to 
determine the reaction diastereoselectivity under these circumstances.  This observation 
suggested that this system is not a good candidate for the asymmetry conjugate addition reaction. 
Hence, no further analysis was conducted on the reaction mixture.  
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Initial attempts to increase the diastereoselectivity of the conjugate addition: The L-
phenylalaninol-N4-isopropyl oxadiazinone synthesis and application 
 
While the results from the asymmetric conjugate addition using the Ephedra-based 
oxadiazinones resulted in a diastereoselectivity of 5:1, there was still an interest in pursuing the 
development of an optimal chiral oxadiazinone template. It was proposed that the N4-p-
methoxybenzyl group did not provide enough steric volume to influence the conjugate addition. 
Based on the limitation of the N4-p-methoxybenzyl system to generate the desired level of 
diastereoselection, a new oxadiazinone was envisioned wherein the N4-substituent would be 
more sterically demanding. To this end, a new oxadiazinone bearing an N4-isopropyl group was 
proposed in the place of the former N4-p-methoxybenzyl substituent (Figure 24). 
 
Figure 24. Increasing the steric demand of the N4-substituent. 
 
 
Unfortunately, the proposed oxadiazinone (92) could not be prepared, as the chiral beta-
amino alcohol template, (1R,2S)-norephedrine (74), was no longer commercially available from 
the only United States supplier, Sigma-Aldrich chemical (Merck KGaS)67, as noted earlier. To 
circumvent this problem, beta-amino alcohols sourced from commonly available alpha-amino 
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acids were selected as the new chiral template (Figure 25). Thus, L-phenylalaninol (85) was 
employed in the newly proposed oxadiazinone (94). This new oxadiazinone would have the 
benefit of being sourced from an inexpensive, commonly available chiral starting material and 
offer a larger steric volume at the N4-position, and potentially lead to higher diastereoselection in 
the asymmetric conjugate addition process.  
 
Figure 25. The design of a new L-phenylalaninol based N4-isopropyloxadiazinone. 
 
 
 
Synthesis of the L-phenyl alaninol based N4-isopropyloxadiazinone 
 
The synthesis of this oxadiazinone began with the reductive amination68,69 of 
commercially available L-phenylalaninol (85) with reagent grade acetone in the presence of 
acetic acid and sodium triacetoxyborohydride (Scheme 31). This process afforded the target N4-
isopropyl-L-phenyl-alaninol (94c) in 44% yield. The N4-isopropyl-L-phenylalaninol was then 
subjected to an N-nitrosation reaction in the presence of sodium nitrite, an aqueous solution of 
HCl (3M), and tetrahydrofuran.70,71 This reaction resulted in a near quantitative isolation of the 
N-nitrosamine product (94d) as a mixture of diastereomers with a percentage yield of 94%. At 
this stage, the N-nitrosamine needed to be reduced to the hydrazine (94f). Our research group 
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had used lithium aluminum hydride (LiAlH4)72-74 to accomplish this task, but we wanted to 
pursue a reduction pathway that was more efficient and less dangerous. Thus, without further 
purification, the N-nitrosamine was reduced using the method of Kandasamy and coworkers,75 in 
which the N-nitrosamine was reacted with formamidine sulfinic acid (94e) in the presence of an 
aqueous solution of sodium hydroxide (1M) and methanol. This process yielded the desired 
hydrazine product (95) in 84% yield.  
 
Scheme 31. Synthesis of the L-phenylalaninol based N4-isopropyloxadiazinone. 
 
 
A potential reaction mechanism for this transformation is illustrated in Scheme 32.  The 
overall reaction mechanism is divided into two stages. The first stage involves the decomposition 
of the formamidine sulfinic acid (94e) to give urea (95b) and ultimately, sulfoxylic acid (95e). In 
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the second stage, the sulfoxylic acid reduces the nitrosamine by a process of nucleophilic 
addition and elimination of sulfur dioxide in two independent steps. 
 
Scheme 32. Mechanism for the formamidine sulfinic acid reduction of N-nitrosamine 58.  
 
 
 
The hydrazine (95) thus obtained, without further purification, was then reacted with 
carbonyl diimidazole for 18 hours to induce cyclization as described in the method developed by 
Husson and coworkers53 to obtain the target N4-isopropyloxadiazinone (94). The crude product 
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was then subjected to column chromatography purification in a 50:50 hexanes: ethyl acetate 
solvent system, resulting in an isolated chemical yield of 77%. 
 
Acylation and asymmetric conjugate addition with the N4-isopropyloxadiazinone 
 
The pure heterocycle (94) obtained from the cyclization reaction was taken through 
acylation reaction using the two pathways of trans-cinnamic acid and crotonyl chloride. The 
acylation reaction with trans-cinnamic acid was carried out in the presence of 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC) coupling agent, 4-dimethylaminopyridine (DMAP) 
catalyst and anhydrous dichloromethane (Scheme 33) to yield the cinnamoyl acylated 
oxadiazinone (96) in a 30% yield after chromatography purification in a 75:25 hexanes: ethyl 
acetate solvent system. The N3-crotonyl variation was prepared by reacting the heterocycle (94) 
with trans-crotonyl chloride in the presence of sodium hydride and anhydrous dichloromethane 
(Scheme 34). The process yielded the acylated heterocycle (97) in an unoptimized yield of 18% 
after chromatography purification (75:25 hexanes: ethyl acetate). 
 
Scheme 33. Synthesis of N4-isopropyl-N3-cinnamoyloxadiaxinone.  
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Scheme 34. Synthesis N4-isopropyl-N3-crotonyloxadiaxinone. 
 
 
 
The N4-isopropyl-N3-cinnamoyloxadiaxinone (96) was further subjected to a conjugate 
addition reaction (Scheme 35) reaction using Normant reagent (methyl magnesium bromide and 
cupper (I) bromide dimethyl sulfite complex) in the presence of tetrahydrofuran. The target N3-
(3-methylcinnamoyl)- N4-isopropyl oxadiazinone (98) was isolated as a mixture of diastereomers 
(98a & 98b) in a 47% yield after chromatography purification (85:15 hexanes: ethyl acetate). 
 
Scheme 35. Synthesis of the N3-(3-methylcinnamoyl)- N4-isopropyl oxadiazinone (98) 
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Upon analysis of the crude prosuct with 500 MHz 1H NMR, These products yielded an 
integration ratio of  1.5:1 in favor of the major diastereomer (Figure 26). 
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Figure 26. 500 MHz 1H NMR spectrum of the N4-isopropyl-N3-(3-methylcinnamoyl) 
oxadiazinone diastereomers (98a & 98b) conjugate addition product. 
 
 
Following the same reaction procedure as the cinnamoyl derivative, the N3-crotonyl-N4-
isopropyloxadiaxinone (97) was reacted with methyl magnesium bromide and cupper (I) 
bromide dimethyl sulfite complex in the presence of tetrahydrofuran (Scheme 36) to yield the 
target N3-(3-phenylbutanoyl)-N4-isopropyl oxadiazinone (99) as a mixture of diastereomers (99a 
& 99b) in a 70% yield after chromatography purification (85:15 hexanes: ethyl acetate).      
                                                                                                                                                                                                   
 
 
 
 
 
55 
 
Scheme 36. Synthesis of the N3-(3-phenylbutanoyl)- N4-isopropyl oxadiazinone (75a & 75b) 
 
 
 
The crude conjugate addition product was analysized with 500 MHz 1H NMR and a 
diastrereomeric ratio of 1.6:1 was observed in favor of the major isomer (Figure 27). 
 
Figure 27. 500 MHz 1H NMR spectrum of the N4-isopropyl-N3-(3-phenylbutanoyl) 
oxadiazinone (99a & 99b) diastereomers. 
 
 
 
56 
 
The low diastereoselectivity observed for the N4-isopropyl system was not what was 
expected. This set us thinking on what could be responsible for such outcome and it was again 
reasoned that this could be as a result of flexibilities around the N3-position of the acylated 
starting material (Figure 28) as seen in the case of the para-methoxybenzyl (PMB) systems. 
 
Figure 28. Potential alteration of configuration in the conjugate addition starting material for the 
isopropyl system. 
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It was proposed that the steric volume of the isopropyl group caused the acyl side chain 
to adopt another orientation. At this point, the reaction condition for the asymmetric aldol 
addition reaction (the use of titamum reagent)76,77 was considered a possible solution to the 
flexibily problem. Hence, the isopropyl oxadiazinone was taken through some titanium 
chemistry, believing that complexing the material with metal compound such as titanium 
tetrachloride (TiCl4) would hold the structure in place and give the reaction a better 
diastereoselectivities (Figure 29). 
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Figure 29. Proposed solution to the configuration flexibility of the isopropyl system. 
 
 
On this basis, the N3-cinnamoyl-N4-isopropyloxadiaxinone starting material (94) was 
taken through three separate conjugate addition reactions using titanium tetrachloride (TiCl4), 
titanium (IV) isopropoxide (Ti(OiPr)4) and methylmagnesium bromide. In the first reaction with 
TiCl4, the acylated heterocycle was reacted with methyl magnesium bromide and TiCl4 at -78 ℃ 
in the presence of tetrahydrofuran (Scheme 36A). The second reaction followed the same 
protocol but in this case, the TiCl4 was replaced with (Ti(OiPr)4) (Scheme 36B). The third 
reaction was conducted at -10 ℃ using only methyl magnesium bromide (Scheme 37C). The 
proton NMR for the first and third reactions showed some evidence of endocyclic nucleophilic 
attack on the heterocycle rather than conjugate addition, resulting in ring opening and formation 
of hydrazines and carboxylic acids while the second reaction gave some addition products that 
could not be identified by proton NMR analysis. 
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Scheme 37. Observation from the 500 MHz 1H NMR spectra of the metal complexing reactions 
with the N4-isopropyl-N3-(3-phenylbutanoyl) oxadiazinone. 
 
 
 
Further attempts to increase the diastereoselectivity of the conjugate addition:  
The L-phenylalaninol-N4-diphenylmethyloxadiazinone and the  
L-phenylalaninol-N4-(1,3-diphenyl-2 propyl) oxadiazinone 
 
Having examined the Ephedra-based oxadiazinones, the N4-para-methoxybenzyl 
substituted oxadiazinones and the N4-isopropyl substituted oxadiazinone and the 
diastereoselectivities in all cases were lower than the desired diastereoselectivity (99:1 or 
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greater), more oxadiazinone derivatives, the L-phenylalaninol-N4-(1,3-diphenyl-2 propyl) 
oxadiazinone (101) and the L-phenylalaninol-N4-diphenylmethyl oxadiazinone (102) (Figure 30) 
will be synthesized and applied in the asymmetric conjugate addition reactions to determine if a 
better diastereoselectivity can be obtained through these new systems. 
 
Figure 30. Proposed design improvement of the N4-substituted oxadiazinone. 
 
 
A proposed reaction pathway to the synthesis of these new oxadiazinones are described below. 
 
Proposed attempt to increase the diastereoselectivity of the conjugate addition: the 
N4-1,3-diphenyl-2-propyloxadiazinone 
 
In a bid to improve the diastereoselectivity over the N4-position of the oxadiazinone, a 
new ring system will be pursued. This new system involves the replacement of the isopropyl 
group at the N4-position with the much larger 1,3-diphenyl-2-propyl group (Figure 31). 
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Figure 31. Structural comparison between the N4-isopropyl and the N4-1,3-diphenyl-2-propyl 
oxadiazinones. 
 
 
 
The synthesis of this system will be accomplished by reacting the L-phenylalaninol (85) 
starting material with 1,3-diphenylpropan-2-one (103) in the presence of sodium 
triacetoxyborohydride and acetic acid (Scheme 38) to obtain the amino alcohol N4-(1,3-diphenyl-
2-propyl)-L-phenyl-alaninol (104) which will then be subjected to N-nitrosation reaction using 
sodium nitrite and an aqueous solution of HCl (3M) using THF solvent to obtain N-nitrosamine 
(105).The N-nitrosamine can then be subjected to reduction reaction in the presence of 
formamidinesulfinic acid (94a), an aqueous solution of sodium hydroxide (1M), and methanol. 
This will be immediately followed with the cyclization of the hydrazine in the presence of 
carbonyl diimidazole (55) and tetrahydrofuran to obtain the N4-1,3-diphenyl-2-
propyloxadiazinone. 
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Scheme 38. Proposed synthesis of the L-phenyl alaninol based N4-1,3-diphenyl-2-
propyloxadiazinone. 
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Proposed acylation and asymmetric conjugate addition with the N4-1,3-diphenyl-2-
propyloxadiazinone 
 
The N4-1,3-diphenyl-2-propyl heterocycle obtained from the above process will be taken 
through the Steglich and crotonyl acylation reactions (Scheme 39). The acylated product will in 
turn be subjected to the conjugate addition reactions (Scheme 40). The conjugate addition 
products that will be obtained will then be analyzed by proton NMR to determine the 
stereoselectivities of the new cyclic system. 
 
Scheme 39. Proposed Steglich reaction (top) and crotonyl acylation of the N4-1,3-diphenyl-2-
propyloxadiazinone. 
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Scheme 40. Proposed asymmetric conjugation addition with the N4-1,3-diphenyl-2-
propyloxadiazinone. 
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A few reactions have been conducted with the L-phenylalaninol-N4-(1,3-diphenyl-2-
propyl) oxadiazinone (101) which were not very successful. The system is still under study to 
determine the best reaction conditions for the oxadiazinone synthesis. 
 
Proposed attempt to increase the diastereoselectivity of the conjugate addition: 
N4-diphenylmethyloxadiazinone 
 
The next oxadiazinone that will be examined is the L-phenylalaninol-N4-diphenylmethyl 
oxadiazinone (102). In this system, the N4-substituent will be the much larger diphenylmethyl 
group (Figure 32). As a matter of fact, work has already begun on the synthesis of this 
oxadiazinone. The first three reactions (reductive amination, reduction and nitrosation) have 
been successfully conducted (Scheme 41).  
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Figure 32. Structural comparison between the N4-1,3-diphenyl-2-propyl oxadiazinones (101) 
and the N4-diphenylmethyl oxadiazinones (102). 
 
 
Scheme 41. Synthesis of the N4-diphenylmethyl oxadiazinones (102). 
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The synthesis began with the reaction of the L-phenylalaninol (85) starting material with 
benzophenone imine (111) in the presence of anhydrous dichloromethane. The target 
benzophenone imine of phenylalaninol (112) was obtained as a yellow solid in a 97% yield after 
recrystallization. This was followed by reduction of the benzophenone imine of phenylalaninol 
using sodium borohydride in the presence of methanol and tetrahydrofuran which yielded the 
reduced amino alcohol (113) in a near quantitative yield of 97%. The next step was the N-
nitrosation of the benzophenone imine of phenylalaninol; however, there was a concern that the 
substrate would undergo acid catalyzed deprotection of the diphenyl methyl group under the 
standard conditions of N-nitrosation (sodium nitrite/hydrochloric acid). To this end, the substrate 
was reacted with tert-butyl nitrite (116)78 (Scheme 42) to circumvent the direct use of an acidic 
solution. 
 
Scheme 42. Attempted N-nitrosation of N-diphenylmethyl-L-phenylalaninol.  
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Unfortunately, the use of tert-butyl nitrite failed to successfully cause the N-nitrosation of 
the N-diphenylmethyl-L-phenylalaninol substrate.  This was evident from the complexity of the 
500 MHz 1H NMR spectrum of the crude reaction mixture and from the analysis of the thin layer 
chromatography plate that suggested the presence of starting material, the N-nitrosation 
products, and other unidentified byproducts. To resolve this problem, sodium nitrite (NaNO2) 
and aqueous hydrochloric acid (HCl) (the original reaction conditions) were reconsidered. Thus, 
the starting material was dissolved in THF and hydrochloric acid and reacted with sodium nitrite 
(Scheme 43). We were gratified to learn that the N-nitrosation reaction was more successful 
under these new conditions. This process resulted in the formation of the target product (114) in 
conjunction with benzophenone through some deprotection/oxidation pathway. The product was 
isolated as a mixture of diastereomers (114a & 114b) in a 94% yield. 
 
Scheme 43. N-nitrosation of N-diphenylmethyl-L-phenylalaninol with sodium nitrite and 
hydrochloric acid. 
 
 
The N-nitrosamine (114) obtained in this process will be subjected to reduction reaction 
using the formamidine sulfinic acid (94a) reaction conditions to obtain the N4-diphenylmethyl 
substituted hydrazine (115) which will be immediately followed with cyclization in the presence 
of carbonyl diimidazole (55) and tetrahydrofuran to obtain the N4-1,3-diphenylmethyl 
oxadiazinone (102). 
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CHAPTER III: CONCLUSION AND FUTURE DIRECTIONS 
 
In search of a suitable chiral template for the synthesis of the medicinal agent tolterodine 
via asymmetric conjugate addition, a series of heterocycles known as oxadiazinones were 
synthesized. These compounds were then applied in asymmetric conjugate addition reactions and 
analyzed. 
  First, three members of the Ephedra alkaloids, namely (1R,2S)-ephedrine; (1S,2S)-
pseudoephedrine and (1R,2S)-norephedrine were employed in the synthesis of the corresponding 
oxadiazinones. This was followed by the use of α-amino acid, L-phenyl alaninol, as a precursor 
for the synthesis of the oxadiazinones. 
Of the three members of the Ephedra alkaloid family, the ephedrine-based oxadiazinone 
yielded the highest diastereoselectivity when subjected to asymmetric conjugate addition 
reaction conditions. In contrast, the pseudoephedrine based oxadiazinone displayed a significant 
line broadening of diagnostic peaks in both 1H NMR and 13C NMR spectra of the acylated 
product, an indication that the molecule is conformationally flexible. This kind of line 
broadening was also observed in one of the L-phenylalaninol based systems. 
It was projected that having a more sterically demanding substituent at the N4-position 
(the stereochemical controlling element) of the oxadiazinones would help in improving the 
diastereoselectivity. However, the observed result was that the diastereoselectivity of the 
asymmetric conjugation decreased. Upon replacing the methyl group at the N4-positions of the 
ephedrine and pseudoephedrine oxadiazinones with para-methoxy benzyl (PMB) and isopropyl 
groups in L-phenyl alaninol based oxadiazinones, a subsequent decrease in diastereoselectivity 
was observed. This implies that, as the steric bulk increases, diastereoselectivity decreases. This 
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was reasoned to be due to structural flexibility due to the steric hinderance constituted by the 
bulkiness of the N4-substrituent. 
Complexing the acylated heterocycles with a transition metal in order to improve the 
compounds’ conformational rigidity was considered a possible remedy. Titanium tetrachloride 
and titanium isopropoxide were used as the complexing agents. However, the results observed 
showed no indication of asymmetric conjugate addition. Metals other than titanium may 
ultimately give a different result. 
In terms of future works, other metals will be considered in achieving conformational 
rigidity of the acylated substrates. Also, the conjugate addition products will be taken through 
hydrolysis in order to recover the chiral carboxylic acid side chains which will thereafter be 
employed in the synthesis of the medicinal agent tolterodine. 
Overall, the oxadiazinones have proven to be a viable chiral template in aldol addition reaction 
and has shown potentials in conjugate addition. These compounds will be further developed to 
obtain an improved diastereoselectivity of the system.   
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APPENDIX A: EXPERIMENTALS 
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General Remarks: Chemical reagents and solvents were purchased from commercial vendors 
and used without further purification. All reactions were conducted in flame-dried or oven dried 
glassware under a nitrogen atmosphere. Solvents were removed by rotary evaporation and 
further dried by a Welch DryFast mechanical pump. All 1H and 13C NMR spectra were recorded 
in deuterated chloroform (CDCl3) using an NMR spectrometer operating at 500 and 400 MHz for 
1H NMR and operating at 125 and 100 MHz for 13C NMR. Chemical shifts were reported in 
parts per million (δ scale) and coupling constant (J values) are listed in Hertz (Hz). 
Tetramethylsilane (TMS) was used as internal standard (δ = 0 ppm). Major isomers were 
reported except otherwise stated. OH and NH peaks were reported except when not observed. 
Infrared spectra were reported in reciprocal centimeters (cm-1) and were measured in nujol mull, 
regular chloroform or as a neat liquid. Melting points were recorded on a Mel-Temp apparatus 
and were uncorrected. All polarimetric experiments were carried out using a Jasco P-2000 
polarimeter. 
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N-nitrosamine of (1R,2S)-Ephedrine (53): The (1R,2S)- ephedrine substrate (52) (20.00 g, 
121.0 mmol) was placed in a 250 mL round bottom flask and dissolved in tetrahydrofuran (THF) 
(40 mL). This was followed with the addition of an aqueous hydrochloric acid (51 mL, 2.74 M, 
139 mmol) and sodium nitrite (9.60 g, 139 mmol) and the reaction was left stirring for 24 h. The 
mixture was then made basic through dilution with saturated aqueous solution of NaHCO3 and 
then extracted with ethyl acetate (75 mL) followed by brine wash. The organic product was dried 
with MgSO4, filtered under gravity and solvents-removed under reduced pressure to yield 22.21 
g (95%) of the target molecule as a yellow solid: MP: 92-94 ℃. 1H NMR (CDCl3): δ = 1.47 (d, J 
= 7.0 Hz, 3H), 2.40 (bs, 1H), 2.96 (s, 3H), 4.69 (quintet, J = 7.0 Hz, 1H), 5.07 (d, J = 5.1 Hz, 
1H), 7.35-7.37 (m, 5H). 13C NMR (CDCl3): δ = 13.4, 31.4, 65.3, 74.6, 126.4, 128.4, 128.8, 
141.0. IR (KBr): 3374, 2983, 1452 cm-1.  
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(1R,2S)-2-methylamino-N-amino-1-phenyl-1-propanol (54): The reducing agent lithium 
aluminum hydride (LiAlH4) (12.3 g, 325 mmol) and the solvent tetrahydrofuran (THF) (300 mL) 
were placed in a flame-dried, nitrogen-purged, 5 L, 3-neck round bottom flask set up with an 
addition funnel and a condenser. The mixture was then heated under reflux. This was followed 
with the addition of the nitrosamine substrate (53) (21.0 g, 108 mmol) which was pre-dissolved 
in THF. The addition was carried out via the addition funnel over a period of 30 min. The 
reaction mixture was thereafter maintained under reflux for another 5 hrs. after which it was 
cooled to room temperature. Once at room temperature, NaOH (6M) was carefully added to the 
reaction vessel to consume any unreacted LiAlH4. The reaction was then extracted with ethyl 
acetate (150 mL) and washed with brine (100 mL). The recovered organic product was then 
dried with MgSO4, filtered under gravity and solvents-removed under reduced pressure to yield 
18.0 g (93%) of the target molecule as a yellow viscous oil: 1H NMR (CDCl3): δ = 0.83 (d, J = 
6.7 Hz, 3H), 2.59 (s, 3H), 2.76 (dq, J = 6.7, 1.5 Hz, 1H), 5.21 (s, 1H), 7.21-7.39 (m, 5H). IR 
(KBr): 2978, 1619, 1046 cm-1. 
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(5R,6S)-4,5-Dimethyl-6-phenyl-1,3,4-oxadiazin-2-one (34): The (1R,2S) hydrazine substrate 
(54) (14.3 g, 79.4 mmol) was placed in a flame-dried, nitrogen-purged 500 mL round bottom 
flask and dissolved in THF (200 mL). To the solution was added p-toluene sulfonic acid 
monohydrate (15.1 g, 87.4 mmol) followed with the addition of 1,1-carbonyldiimidazole (14.2 g, 
87.4 mmol). The resulting mixture was heated under reflux for three hours after which it was 
cooled to room temperature, followed with addition of an aqueous solution of sodium 
bicarbonate (50 mL). The reaction was then extracted with ethyl acetate (50 mL) and washed 
with brine (50 mL). The recovered organic product was dried with MgSO4, filtered under gravity 
and solvents-removed by rotary evaporation to yield 12.1 g (74%) of the target molecule as a 
white solid: MP: 118-120 ℃. 1H NMR (CDCl3): δ = 1.02 (d, J = 7.0 Hz, 3H), 3.03 (s, 3H), 3.44 
(dq, J = 4.3, 7.0 Hz, 1H), 6.05 (d, J = 4.3 Hz, 1H), 7.13-7.15 (m, 1H), 7.24-7.26 (m, 2H), 7.29-
7.30 (m, 2H). 13C NMR: δ = 11.7, 46.6, 57.0, 74.2, 125.3, 128.0, 128.6, 136.2, 152.2. IR (KBr): 
3228, 2943, 1686 cm-1. ESI HRMS for C11H14N2NaO2+: calcd (M + Na+) 229.0947, found 
229.0950. 
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(5S,6R)-3-trans-Cinnamoyl-N4-p-methoxybenzyl-4-methyl-6-phenyl-1,3,4-oxadiazinone 
(43): To a flame dried, nitrogen purged 250 mL round bottom flask was added trans-cinnamic 
acid (1.29 g, 8.72 mmol) and dissolved in anhydrous dichloromethane (16 mL). This was 
followed with the addition of the coupling agent 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) (1.671 g, 8.72 mmol), the 4-dimethylaminopyridine (DMAP) catalyst 
(0.134 g,1.09 mmol) and the oxadiazinone substrate (0.900 g, 4.36 mmol), sequentially and left 
stirring at room temperature for 16 hours. The reaction was then diluted with dichloromethane 
(80 mL) and washed with 1 M HCl (20 mL), 1M NaOH (20 mL) (twice) followed by brine (20 
mL) wash. The organic layer thus recovered was dried over magnesium sulfate, gravity filtered, 
and solvent removed under reduced pressure. The crude product obtained was purified by flash 
column chromatography (hexane: ethyl acetate, 70:30) to yield the title compound (1.034 g, 
71%) as a white solid: MP: 125-128 ℃. 1H NMR (CDCl3): δ = 0.93 (d, J = 7.0 Hz, 3H), 3.08 (s, 
3H), 3.48 (dq, J = 6.9, 4.6 Hz, 1H), 6.12 (d, J = 4.6 Hz, 1H), 7.34-7.38 (m , 3H), 7.41-7.45 (m, 
5H), 7.61-7.64 (m, 3H), 7.88 (d, J = 15.6 Hz, 1H).  13C NMR (CDCl3): δ = 12.7, 43.8, 56.9, 77.9, 
119.0, 125.0, 128.2, 128.4, 128.7, 128.9, 130.5, 134.8, 135.8, 145.8, 148.1, 166.6. IR (CHCl3): 
1730, 1704, 1623, 1267, 1197, 724, 703 cm-1. ESI HRMS for C20H20N2NaO3+: calcd (M + Na+) 
359.1366, found 359.1366. 
 
81 
 
 
 (5S,6R)-4-para-Methoxybenzyl-4-methyl-6-phenyl-3-(3’-phenylbutanoyl)-1,3,4-
oxadiazinone (59): To a 100 mL flame dried, nitrogen purged three-neck round bottomed flask 
was added copper bromide dimethyl sulfide complex (0.933 g 4.54 mmol), tetrahydrofuran 
(THF) (5 mL) by syringe and dimethyl sulfide solvent (5 mL) by syringe, one after the other. 
The reaction was then cooled to a temperature of -78 oC in a dry ice/ ethanol bath. Methyl 
magnesium bromide (1.51 mL, 4.54 mmol) was then carefully added to the solution by syringe 
and left to stir for 45 minutes at -78 oC. The N3-cinnamoyloxadiaxinone (43) substrate (0.509 g, 
1.51 mmol) was dissolved in THF (6 mL) and then added by dropwise addition to the reaction 
vessel through an addition funnel. The reaction was left stirring for 17 hours while it gradually 
warmed up to room temperature. The reaction was then diluted with ethyl acetate (80 mL) and 
washed with 1M NaOH (20 mL), 1 M HCl (20 mL) and brine solution (20 mL). The recovered 
organic layer was dried with magnesium sulfate, filtered under gravity and solvent removed 
under high vacuum. The crude product obtained was purified by flash column chromatography 
(Hexane: ethyl acetate, 70:30) to yield 0.348 g (65%) of the titled compound as a colorless 
viscous oil. Only the major isomer is reported:  1H NMR (CDCl3): δ = 0.79 (d, J = 7.0 Hz, 3H), 
1.32 (d, J = 6.8 Hz, 3H), 2.82 (s, 3H), 3.11 (dd, J = 7.6, 16.4 Hz, 1H), 3.27-3.49 (m, 3H), 5.99 (d, 
J = 4.4 Hz, 1H), 7.15-7.20 (m, 1H), 7.25-7.29 (m, 6H), 7.31-7.34 (m, 1H), 7.37-7.41 (m, 2H). 
13C NMR (CDCl3): δ = 12.4, 21.8, 36.2, 43.3, 45.9, 56.8, 124.9, 126.3, 127.1, 128.2, 128.4, 
128.7, 135.7, 146.0, 148.4, 172.6. IR (CHCl3): 1778, 1724, 1257, 1137, 744, 700 cm-1. ESI 
HRMS for C21H24N2NaO3+: calcd (M + Na+) 375.1679, found 375.1678. 
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(S)-(+)-3-Phenylbutanoic acid (60a): To a racemic mixture of (S)-(+)-3-Phenylbutanoic acid 
(60a) and (R)-(+)-3-Phenylbutanoic acid (60b) (5.24 g, 31.9 mmol) in a 250 mL beaker was 
added the chiral amine (S)-(-)-1-phenylethylamine (61) (3.90 g, 31.9 mmol), ethanol (100%) (13 
mL) and deionized water (15 mL). The mixture was stirred gently until a homogeneous solution 
was obtained. The solution was then left to stand at room temperature for about 15 minutes to 
allow the formation of the carboxylate diastereomeric crystal salt (62b). The crystals formed 
(4.16 g) was recovered by vacuum filtration. The recovered crystals were subjected to second 
recrystallization by dissolution in ethanol and deionized water solution (15 mL each) by means 
of heating and spinning at 50 ℃ on a rotary evaporator. The homogenous solution was allowed 
to stand at room temperature till crystals were reformed. The crystals (3.15 g) were again 
collected by vacuum filtration. The carboxylate salt was then extracted with diethyl ether (80 
mL) and aqueous hydrochloric acid (1M) (50 mL) to yield 1.26 g (48%) of the (S)-(+)-3-
Phenylbutanoic acid (60a) as a colorless liquid. 1H NMR (CDCl3): δ = 1.30 (d, J = 6.9 Hz, 3H), 
2.58 (dd, J = 8.3, 15.6 Hz, 1H), 2.67 (dd, J = 6.9, 15.6 Hz, 1H), 3.27 (sxt, J = 7.5, 14.7 Hz, 1H), 
7.19-7.23 (m, 3H), 7.29-7.32 (m, 2H); 13C NMR (CDCl3): δ = 21.9, 36.2, 42.7, 126.5, 126.7 
128.6 145.5, 178.9; IR (neat): 2970, 1706, 1296, 763, 700 cm-1 ESI HRMS for C11H14N2NaO2+: 
calcd (M + Na+) 187.0730, found 187.0730. 
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N-nitrosamine of (1S,2S)-pseudoephedrine (68): The (1S,2S)-pseudoephedrine substrate 
(20.00 g, 121.0 mmol) was placed in a 250 mL round bottom flask together with Tetrahydrofuran 
(THF) (50 mL). This was followed with the addition of an aqueous hydrochloric acid (50.8 mL, 
2.74 M, 139 mmol) and sodium nitrite (9.60 g, 139 mmol) and the reaction was left stirring for 
24h. The mixture was then made basic through dilution with saturated aqueous solution of 
NaHCO3 and then extracted with ethyl acetate (75 mL) followed by brine wash (25 mL). The 
organic product was dried with MgSO4, filtered under gravity and solvents-removed under 
reduced pressure to yield 22.9 g (97%) of the target molecule as a yellow solid after 
recrystallization (EtOAc-hexanes, 1:1): MP: 85-86 ℃. 1H NMR (CDCl3): δ = 1.29 (d, J = 6.6 
Hz, 3H), 2.44 (bs, 1H), 3.07 (s, 3H), 4.75-4.86 (m, 2H), 7.32-7.41 (m, 5H). 13C NMR (CDCl3): δ 
= 16.0, 30.2, 65.1, 76.4, 126.8, 128.6, 128.9, 140.4. IR (KBr): 3480, 3032, 1465, 1268, 820, 721 
cm-1. 
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(1S,2S)-2-methylamino-N-amino-1-phenyl-1-propanol (69): The reducing agent lithium 
aluminum hydride (LiAlH4) (13.4 g, 353 mmol) and the solvent tetrahydrofuran (THF) (400 mL) 
were placed in a flame-dried, nitrogen-purged, 5 L, 3-neck round bottom flask set up with an 
addition funnel and a condenser. The mixture was then heated under reflux. This was followed 
with the addition of the nitrosamine substrate (68) (22.9 g, 118 mmol) which was pre-dissolved 
in THF. The addition was carried out via the addition funnel over a period of 30 min. The 
reaction mixture was thereafter maintained under reflux for another 5 hrs. after which it was 
cooled to room temperature. Once at room temperature, NaOH (6M) was carefully added to the 
reaction vessel to consume any unreacted LiAlH4. The reaction was then extracted with ethyl 
acetate (150 mL) and washed with brine (100 mL). The recovered organic product was then 
dried with MgSO4, filtered under gravity and solvents-removed under reduced pressure to yield 
21.1 g (99%) of the target molecule as a yellow viscous oil: 1H NMR (CDCl3): δ = 0.79 (d, J = 
6.6 Hz, 3H), 2.58 (s, 3H), 2.63-2.69 (m, 1H), 4.42 (d, J = 9.2 Hz, 1H), 7.27-7.38 (m, 5H). IR 
(KBr): 3333, 2975, 754, 701 cm-1. 
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(5S,6S)-4,5-Dimethyl-6-phenyl-1,3,4-oxadiazin-2-one (70): The (1S,2S) hydrazine substrate 
(69) (2.86 g, 15.9 mmol) was placed in a flame-dried, nitrogen-purged 100 mL round bottom 
flask and dissolved in THF (100 mL). To the solution was added p-toluene sulfonic acid 
monohydrate (3.02 g, 15.88 mmol) followed with the addition of 1,1-carbonyldiimidazole (3.09 
g, 19.1 mmol). The resulting mixture was heated under reflux for three hours after which it was 
cooled to room temperature and an aqueous solution of sodium bicarbonate (50 mL) was added. 
The reaction was then extracted with ethyl acetate (50 mL) and washed with brine (50 mL). The 
recovered organic product was dried with MgSO4, filtered under gravity and solvents-removed 
by rotary evaporation to yield 2.40 g (74%) of the target molecule as a white solid after 
chromatography purification: MP: 97-98 ℃. [α]23D +30.1o (THF).  1H NMR (CDCl3): δ = 0.96 (d, 
J = 6.8 Hz, 3H), 2.69 (s, 3H), 3.22 (dq, J = 6.8, 9.9 Hz, 1H), 5.25 (d, J = 9.9 Hz, 1H), 7.31-7.34 
(m, 3H), 7.36-7.41 (m, 3H), 7.65 (s, 1H). 13C NMR (CDCl3): δ = 14.3, 40.0, 58.8, 80.7, 127.1, 
128.7, 129.0, 136.6, 153.0. IR (KBr): 3240, 1699, 755, 700 cm-1. 
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(4S,5S)-3-trans-Cinnamoyl-4,5-dimethyl-6-phenyl-1,3,4-oxadiazinone (71): trans-Cinnamic 
acid (2.58 g, 17.4 mmol) was added to a flame dried, nitrogen purged 250 mL round bottom 
flask and dissolved in anhydrous dichloromethane (16 mL). This was followed with a sequential 
addition of the coupling agent 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (3.34 g, 
17.4 mmol), the 4-dimethylaminopyridine (DMAP) catalyst (0.268 g, 2.18 mmol) and the 
oxadiazinone substrate (1.80 g, 8.72 mmol). The reaction was then left stirring for 16 hours at 
room temperature after which the reaction was diluted with dichloromethane (80 mL) and 
washed with 1 M HCl (20 mL), 1M NaOH (20 mL) (twice) followed by brine (20 mL) wash. 
The organic layer thus recovered was dried over magnesium sulfate, gravity filtered, and solvent 
removed under reduced pressure. The crude product obtained was purified by flash column 
chromatography (hexane: ethyl acetate, 75:25) to yield the title compound (1.74 g, 59%) as a 
white fluffy solid. MP: 47-50 ℃. 1H NMR (CDCl3): δ = 1.21 (d, J = 6.8 Hz, 3H), 2.91 (s, 3H), 
3.42 (dq, J = 6.8, 10.4 Hz, 1H).  5.30 (d, J = 9.8 Hz, 1H), 7.36-7.38 (m, 2H), 7.42-7.45 (m, 6H), 
7.53 (d, J = 15.7, 1H), 7.62-7.64 (m, 1H), 7.89 (d, J = 15.7 Hz, 1H). 13C NMR (CDCl3): δ = 15.4, 
38.7, 61.0, 84.1, 118.7, 126.9, 128.4, 128.9, 129.0, 129.3, 130.5, 134.8, 136.0, 145.8, 149.5, 
165.8. IR (CHCl3): 1704, 1626, 1577, 1204, 1128, 1045, 700, 666 cm-1. ESI HRMS for 
C20H20N2NaO3+: calcd (M + Na+) 359.1366, found 359.1358. 
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(5S,6R)-4-para-Methoxybenzyl-4-methyl-6-phenyl-3-(3’-phenylbutanoyl)-1,3,4-
oxadiazinone (72): To a 100 mL flame dried, nitrogen purged three-neck round bottomed flask 
was added copper bromide dimethyl sulfide complex (1.00 g 4.87 mmol), tetrahydrofuran (THF) 
(5 mL) by syringe and dimethyl sulfide solvent (5 mL) by syringe, one after the other. The 
reaction was then cooled to a temperature of -78 oC in a dry ice/ ethanol bath. Methyl magnesium 
bromide (1.62 mL, 4.87 mmol) was then carefully added to the solution by syringe and left to stir 
for 45 minutes at -78 oC. The N3-cinnamoyloxadiaxinone (29) substrate (0.546 g, 1.62 mmol) 
was dissolved in THF (6 mL) and then added by dropwise addition to the reaction vessel through 
an addition funnel. The reaction was left stirring for 17 hours while it gradually warmed up to 
room temperature. The reaction was then diluted with ethyl acetate (80 mL) and washed with 1M 
NaOH (20 mL), 1 M HCl (20 mL) and brine solution (20 mL). The recovered organic layer was 
dried with magnesium sulfate, filtered under gravity and solvent removed under high vacuum. 
The crude product obtained was purified by flash column chromatography (Hexane: ethyl 
acetate, 70:30) to yield 0.451 g (79%) of the titled compound as a colorless oil. 1H NMR 
(CHCl3): δ = 0.96 (d, J = 6.8 Hz, 3H), 1.29 (d, J = 6.9 Hz, 3H), 2.62 (s, 3H), 2.90-3.04 (m, 2H), 
3.25-3.29 (dd, J = 7.7, 15.7 Hz, 1H), 3.35 (sxt, J =  7.1 Hz, 1H), 5.1 (bs, 1H), 7.13-7.18 (m, 4H), 
7.21-7.24 (m, 3H), 7.31-7.33 (m, 3H). 13C NMR (CHCl3): δ = 15.6, 22.0, 36.8, 36.9, 44.7, 45.1 
83.9, 126.5, 126.9, 127.1, 128.5, 128.6, 128.9, 129.3, 135.9, 145.9, 171.9. IR (neat): 1781, 1728, 
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1211, 1126, 760, 700 cm-1. ESI HRMS for C21H24N2NaO3+: calcd (M + Na+) 375.1679, found 
375.1673. 
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(1R,2S)-N-para-Methoxybenzyl-norephedrine (75): To a 1000 mL round bottom flask 
containing (1R,2S)-norephedrine (10.0 g, 66.1 mmol) was added para-anisaldehyde (8.8 mL, 72 
mmol) and 100% methanol (100 mL) to make a solution. To the solution was added two scoops 
of MgSO4 and stirred thoroughly, and the reaction mixture was stirred overnight. At which point 
NaBH4 (3.77 g, 99.2 mmol) was added to the reaction and stirred for another for 2 hours, after 
which NaOH (50 mL, 1M) was added to the reaction mixture and stirred for 1 hour. After which 
most of the ethanol was removed in vacuo and the resulting slurry was reconstituted with 200 
mL ethyl acetate and the organic layer was collected and washed with 50 mL deionized water, 50 
mL brine, dried over MgSO4, filtered and solvents removed in vacuo. The crude product was 
used without further purification in the next step.  
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N-((1R,2S)-2-para-Methoxybenzyl-N-nitrosamino)-1-phenyl-1-propanol (76): To the 1000 
mL round bottom flask containing crude protected (1R,2S)-norephedrine (2.1) was added, THF 
(80 mL) followed by aqueous solution of hydrochloric acid (2M, 50 mL, 100 mmol) and stirred 
to make a solution. To the solution was added NaNO2 (4.6 g, 66.1 mmol) slowly in one portion 
and allowed to stir overnight. The reaction was then extracted in 200 mL ethyl acetate and 
washed with 50mL 1M HCl, 50 mL brine, dried over MgSO4, filtered and solvent removed under 
high vacuum. The crude product obtained was purified by flash column chromatography 
(Hexane: ethyl acetate, 70:30) to give 18.9 g (96%) of the title compound (a mixture of 
diastereomers), as a yellow oil. 1H NMR (CDCl3): δ =  1.46 (d, J = 6.9 Hz, 3H),  3.79 (s , 3H), 
4.26 (dq, J = 5.1, 6.9 Hz, 1H), 4.37 (d, J = 14.6 Hz, 1H), 4.76 (d, J =  14.6 Hz, 1H), 5.09 (d, J = 
5.1Hz, 1H), 6.81 (m, 2H), 6.90 (m, 2H), 6.97 (m, 2H). 13C NMR (CDCl3): δ = 9.80, 15.2, 47.5, 
55.36, 55.38, 59.4, 64.0, 65.0, 73.8, 76.8, 76.9, 77.2, 77.4, 114.0, 114.3, 114.5, 125.8, 126.39, 
126.43, 128.1, 128.4, 128.6, 128.7, 129.6, 133.2, 141.0, 141.3, 159.3, 159.8.  
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(1R,2S)-2-(1-(para-Methoxybenzyl)hydrazinyl)-1-phenyl-1-propanol (77): To a 2000 mL 
flame dried, nitrogen purged three neck round bottom flask fitted with a pressure equalizing 
addition funnel and a water cooled reflux condenser, was added LiAlH4 (4.60 g, 121mmol) 
followed by THF (300 mL) to give a dark gray suspension. Heat was applied and THF brought to 
reflux, at which point N-((1R,2S)-1-hydroxy-1-phenylpropan-2-yl)-N-(4-methoxybenzyl) nitrous 
amide 2.2 (18.1 g, 60.3 mmol) dissolved in THF (150 mL) was poured into the LiAlH4-THF 
mixture dropwise from the addition funnel after which the reaction was stirred under reflux for 3 
hours. By the end, the reaction mixture took the color of pea soup, at which point heat was 
removed and reaction allowed to cool to room temperature. The reaction was quenched with 
dropwise addition of 1M NaOH (100 mL) from addition funnel. Upon addition of NaOH heavy 
precipitate formation was observed. The precipitate was broken into a slurry and allowed to 
settle, the supernatant solution was decanted to a 1000 mL round bottom flask and most of the 
THF was removed under reduced pressure. The concentrated reaction mixture was reconstituted 
with 250 mL ethyl acetate and 70 mL 1M NaOH and the organic layer was separated, and the 
aqueous layer was back extracted with 100 mL ethyl acetate. The organic layers were combined, 
washed with 50 mL brine, dried with MgSO4, filtered and the solvents removed in vacuo. To 
give the crude β-hydroxyhydrazine which went on to the cyclization step. 
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(5S,6R)-4-(para-Methoxybenzyl)-5-methyl-6-phenyl-1,3,4-oxadiazinone (73):  
To a 1000 mL round bottom flask containing the crude hydrazine (77) (17.12 g, 59.80 mmol), 
was added dichloromethane (540 mL) and triethylamine (25.0 mL, 179 mmol) sequentially and 
the resulting solution was cooled in an ice bath. Triphosgene (5.860 g, 19.73 mmol) was then 
added to the cold solution and the reaction was allowed to stir for 16 hours at room temperature 
after which it was washed with 1 M HCl (50 mL) followed by brine wash (50 mL). The organic 
layer was dried over MgSO4 solvent removed under reduced pressure. The crude product 
obtained was purified by flash column chromatography (hexanes: ethyl acetate, 70:30) to give 
the title compound as a yellow viscous oil in a 53% yield over two steps.  1H NMR (CDCl3): δ = 
0.91 (d, J = 6.9 Hz, 3H), 3.25 (dq, J = 6.9 Hz, 3.0 Hz, 1H), 3.83 (s, 3H), 4.02 (d, J = 12.4 Hz, 
1H), 4.15 (d, J =  12.4 Hz, 1H), 5.8 (d, J = 3.0 Hz, 1H), 6.40 (s, 1H), 6.87-6.96 ( m, 2H), 7.28-
7.34 (m, 5H), 7.35-7.42 (m, 2H). 13C NMR (CDCl3): δ = 11.8, 53.9, 55.4, 62.3, 74.7, 114.3, 
125.3, 127.6, 128.0, 128.6, 130.5, 136.5, 152.2, 159.6.   
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N3-trans-Cinnamoyl-N4-p-methoxybenzyl-4-methyl-6-phenyl-1,3,4-oxadiazinone (78): trans-
Cinnamic acid (0.807 g, 5.45 mmol) was added to a flame dried, nitrogen purged 250 mL round 
bottom flask and dissolved in anhydrous dichloromethane (16 mL). This was followed with a 
sequential addition of the coupling agent 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) (1.05 g, 5.45 mmol), the 4-dimethylaminopyridine (DMAP) catalyst (0.110 g, 0.90 mmol) 
and the oxadiazinone substrate (1.42 g, 4.54 mmol). The reaction was then left stirring for 16 
hours at room temperature after which the reaction was diluted with dichloromethane (80 mL) 
and washed with 1 M HCl (20 mL), 1M NaOH (20 mL) (twice) followed by brine (20 mL) wash. 
The organic layer thus recovered was dried over magnesium sulfate, gravity filtered, and solvent 
removed under reduced pressure. The crude product obtained was purified by flash column 
chromatography (hexane: ethyl acetate, 80:20) to yield 1.14 g (80%) of the title compound as a 
white fluffy solid: MP: 57-61°C. 1H NMR (CDCl3): δ = 0.85 (d, J = 7.0 Hz, 3H) 3.47 (dq, J = 
4.8, 7.0 Hz, 1H) 3.82 (s, 3H) 4.20 (d, J= 12.5 Hz, 1H) 4.39 (d, J = 12.5 Hz, 1H) 6.14 (d, J = 4.6 
Hz, 1H) 6.94 (d, J = 8.6 Hz, 2H) 7.26 (d, J = 7.8 Hz, 2H) 7.33 (t, J = 7.3, 1H), 7.39 (d, J =  7.8, 
2H) 7.41-7.43 (m, 3H), 7.47 (d, J = 8.6 Hz, 2H) 7.52 (d, J = 15.7 Hz, 1H) 7.59 (m, 2H) 7.78 (d, 
J = 15.7 Hz, 1H). 13C NMR (CDCl3): δ = 12.5, 52.0, 55.3, 59.3, 78.0, 114.4, 119.1, 124.9, 127.0, 
128.2, 128.4, 128.7, 128.8, 130.4, 130.7, 134.9, 135.9, 145.4, 148.2, 159.8, 166.8. IR (CHCl3): 
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1760, 1727, 1615, 1247, 1216, 1136, 823, 736, 701 cm-1. ESI-HRMS calcd for C27H26N2NaO4 
(M + Na+): 465.1785. Found: 465.1779. 
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N3-trans-Cinnamoyl-N4-p-methoxybenzyl-4-methyl-6-phenyl-3-(3’-phenylbutanoyl)-1,3,4-
oxadiazinone (81): To a flame dried, nitrogen purged three-neck 100 mL round bottomed flask 
was added copper bromide dimethyl sulfide complex (0.696 g, 3.39 mmol), tetrahydrofuran 
(THF) (5 mL) by syringe and dimethyl sulfide solvent (5 mL) by syringe, one after the other. 
The reaction was then cooled to a temperature of -78 oC using dry ice and ethanol. Methyl 
magnesium bromide (1.13 mL, 3.39 mmol) was then carefully added to the solution by syringe 
and left to stir for 45 minutes at -78 oC. The N3-cinnamoyloxadiaxinone (x) substrate (0.500 g, 
1.13 mmol) was dissolved in THF (6 mL) and then added dropwise to the reaction vessel via 
addition funnel. The reaction was left stirring overnight, gradually warming up to room 
temperature. The reaction was then diluted with ethyl acetate (80 mL) and washed with 1M 
NaOH (20 mL), 1 M HCl (20 mL) and brine solution (20 mL). The recovered organic layer was 
dried with magnesium sulfate, filtered under gravity and solvent removed under high vacuum. 
The crude product obtained was purified by flash column chromatography (hexanes: ethyl 
acetate, 80:20) to yield 0.321 g (60%) of the titled compound as a yellow viscous oil. 1H NMR 
(CDCl3):  δ = 0.61 (d, J = 7.0 Hz, 3H), 1.20 (d, J = 6.9 Hz, 3H), 2.95 (dd, J = 7.9, 16.7 Hz, 1H), 
3.22-3.27 (m, 3H), 3.30-3.37 (m, 1H), 3.75 (s, 3H), 3.92 (d, J = 12.5 Hz, 1H), 4.01 (d, J = 12.5 
Hz, 1H), 5.93 (d, J = 4.5 Hz, 1H), 6.82-6.85 (m, 2H), 7.07-7.11 (m, 3H), 7.17-7.20 (m, 5H), 
7.25-7.28 (m, 2H), 7.32-7.34 (m, 2H). 13C NMR (CDCl3): δ = 12.3, 21.9, 36.0, 45.6, 51.4, 55.3, 
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58.7, 77.9, 114.3, 124.8, 126.2, 127.0, 127.1, 128.1, 128.5, 128.7, 130.7, 135.9, 146.2, 148.4, 
159.8, 172.6. ESI-HRMS calcd for C28H30N2NaO4 (M + Na+): 481.2098. Found: 481.2090. 
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N3-trans-Crotonyl-N4-p-methoxybenzyl-4-methyl-6-phenyl-1,3,4-oxadiazinone (80): To a 
flame-dried nitrogen-purged 100 mL round bottom flask was added the oxadiazinone substrate 
(0.50 g, 1.6 mmol) which was dissolved in dimethylformamide (DMF) (8.00 mL). To the 
solution was added the sodium hydride base (0.077 g, 3.2 mmol). The reaction was allowed to 
stir for 10 minutes and the crotonyl chloride (0.17 mL, 1.8 mmol) was then added. The reaction 
was left stirring for 18 hours at room temperature, after which it was diluted with 
dichloromethane (50 mL) and washed with 1 M HCl (20 mL) and brine (20 mL). The organic 
layer thus recovered was dried over magnesium sulfate, gravity filtered, and solvent removed 
under reduced pressure. The titled compound was isolated as a yellow solid in a yield of 0.595 g 
(98%) after purification by flash column chromatography (hexanes: ethyl acetate, 80:20): MP: 
54-56 ℃. 1H NMR (CDCl3). δ = 0.77 (d, J = 6.9 Hz, 3H), 1.93 (dd,  J = 1.4, 6.9 Hz, 3H), 3.38  
(dq, J = 4.5, 7.0 Hz, 1H) 3.83 (s, 3H) 4.13 (d, J = 12.6 Hz, 1H) 4.31 (d, J = 12.6 Hz, 1H) 6.07 
(d, J = 4.5 Hz, 1H) 6.92 (d, J = 8.5 Hz, 2H) 7.07 (dq, J = 7.5, 15.2 Hz, 1H) 7.20 (d, J = 7.5 Hz, 
2H) 7.26-7.37 (m, 4H), 7.42 (d, J = 8.5 Hz, 2H). 13C NMR (CDCl3): δ = 12.4, 18.5, 51.5, 55.3, 
59.1, 77.9, 114.3, 123.6, 124.9, 127.0, 128.1, 128.7, 130.7, 135.9, 145.7, 148.2, 159.7, 166.6. IR 
(CHCl3): 1762, 1725, 1639, 1248, 790, 823, 733 cm-1. ESI-HRMS calcd for C22H24N2NaO4 (M + 
Na+): 403.1628. Found: 403.1622. 
 
98 
 
 
 
N3-trans-Crotonyl-N4-p-methoxybenzyl-4-methyl-6-phenyl-1,3,4-oxadiazinone (82): To a 
flame dried, nitrogen purged three-neck 100 mL round bottomed flask was added copper 
bromide dimethyl sulfide complex (0.580 g, 2.82 mmol), tetrahydrofuran (THF) (5 mL, by 
syringe) and dimethyl sulfide solvent (5 mL, by syringe), one after the other. The reaction was 
then cooled to a temperature of -78 ℃ using dry ice and ethanol. Methyl magnesium bromide 
(0.940 mL, 2.82 mmol) was then carefully added to the solution by syringe and left to stir for 45 
minutes at -78 ℃. The N3-crotonyloxadiaxinone (80) substrate (0.358 g, 0.940 mmol) was 
dissolved in THF (6 mL) and then added dropwisely to the reaction vessel via addition funnel. 
The reaction was left stirring for 17 hours while it gradually warmed up to room temperature. 
The reaction was then diluted with ethyl acetate (80 mL) and washed with 1M NaOH (20 mL), 1 
M HCl (20 mL) and brine solution (20 mL). The recovered organic layer was dried with 
magnesium sulfate, filtered under gravity and solvent removed under high vacuum. The crude 
product obtained was purified by flash column chromatography (Hexane: ethyl acetate, 70:30) to 
yield 0.224g (52%) of the titled compound as a yellow viscous oil: (only the major isomer is 
reported) 1H NMR (CDCl3): δ = 0.58 (d, J = 7.0 Hz, 3H), 1.33 (d, J = 7.0 Hz, 3H), 3.17 (dd, J = 
7.3, 16.7 Hz, 1H) 3.29-3.33 (m, 2H), 3.35-3.38 (sxt, J = 6.9 Hz, 1H), 3.85 (s, 3H), 4.07 (d, J = 
12.4 Hz, 1H), 4.19 (d, J = 12.4 Hz, 1H), 6.05 (d, J = 4.6 Hz, 1H) 6.93-6.96 (m, 2H), 7.17-7.21 
(m, 3H), 7.26-7.32 (m, 4H) 7.35-7.38 (m, 2H), 7.42-7.47 (m, 3H). 13C NMR (CDCl3) δ = 12.2, 
22.1, 36.2, 45.6, 51.2, 55.3, 58.6, 78.0, 114.3, 124.8, 126.3, 127.0, 128.1, 128.5, 128.7, 128.8, 
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130.6, 135.9, 146.1, 148.7, 159.7, 172.5. IR (CHCl3): 1775, 1726, 1213, 1136, 850, 740, 700 cm-
1. ESI-HRMS calcd for C28H30N2NaO4 (M + Na+): 481.2098. Found: 481.2100. 
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(S)-(+)-3-phenylbutyric acid (84): The N3-(3-methylcinnamoyl)-N4-para-methoxybenzyl 
oxadiazinone substrate (1.26 g, 2.74 mmol) was added together with acetonitrile (50 mL) into a 
250 mL round bottom flask and homogenized by stirring.  To the homogenized mixture was 
added Ceric ammonium nitrate (Ce(NH4)2NO3) (7.53 g, 13.7 mmol) pre-dissolved in deionized 
water (50 mL). The reaction was left to stir for 3hrs. The mixture was thereafter put on rotary 
evaporator to get rid of the solvents. The concentrated solution was then extracted with diethyl 
ether (50 mL) and brine solution (30 mL). The recovered organic layer was treated with 1M 
NaOH (30 mL) and dried with MgSO4. The aqueous layer was further treated with 3M HCl (30 
mL) and extracted with diethyl ether (50 mL). The second organic product was washed with 
brine and also dried with MgSO4. Both organic products were filtered under gravity and solvent 
removed under high vacuum. The second organic product contained the target molecule and was 
therefore taken through further purification by flash column chromatography (Hexanes-ethyl 
acetate, 80:20). This yielded the title compound (0.10 g, 22%) as a colorless oil: [α]23D   +22. 1H 
NMR (CDCl3): δ = 1.33 (d, J = 7.0 Hz, 3H), 2.58 (dd, J = 8.2, 15.5 Hz, 1H), 2.68 (dd, J = 6.8 
Hz, 1H), 3.28 (sxt, J = 7.0 Hz, 1H), 7.19-23 (m, 3H), 7.29-7.32 (m, 2H). 13C NMR (CDCl3): δ = 
21.9, 36.2, 42.6, 126.5, 126.7, 128.6, 145.5, 178.5. IR (neat): 2970, 1706, 1296, 763, 700 cm-1. 
ESI HRMS for C11H14N2NaO2+: calcd (M + Na+) 187.0730, found 187.0730. 
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N-para-Methoxybenzyl-L-phenylalaninol (86): To a 1000 mL round bottom flask containing 
L-phenylalaninol (15.678 g, 103.7 mmol) was added para-anisaldehyde (14.0 mL, 114 mmol) 
and 100% methanol (150 mL) to make a solution. To the solution was added two scoops of 
MgSO4 and allowed to stir overnight. At which point NaBH4 (5.90 g, 155.5 mmol) was added to 
the reaction and stirred for another for 2 hours, after which 50 mL 1M NaOH was added to the 
reaction mixture and stirred for 1 hour. Then most of the ethanol was removed in vacuo and the 
resulting slurry was reconstituted with 200 mL ethyl acetate and the organic layer was collected 
and washed with 50 mL DI water, 50 mL brine, dried over MgSO4, filtered and solvents 
removed in vacuo to give a crude solid. The crude product was than recrystallized to give the 
title compound as white crystals in 90% yield. MP: 88-90 ℃. 1H NMR (CDCl3): δ = 2.78 (dd, J 
= 6.8, 13.7 Hz, 1H), 2.84 (dd, J = 7.0, 13.7 Hz, 1H), 2.96-3.00 (m, 1H), 3.37 (dd, J = 5.4, 10.8 
Hz, 1H), 3.66 (dd, J = 3.9, 10.8 Hz, 1H), 3.74 (s, 2H), 3.82 (s, 3H), 6.86 (d, J = 8.6 Hz, 2H), 7.15 
(d, J = 8.6 Hz, 2H), 7.19 (d, J = 7.5 Hz, 2H), 7.24-7.28 (m, 1H), 7.30-7.34 (m, 2H).  13C NMR 
(CDCl3): (one of the aromatic carbons was not observed potentially due to coincidental overlap) 
δ = 38.1, 50.6, 55.3, 59.5, 62.7, 113.9, 126.4, 128.6, 129.3, 132.2, 138.7, 158.8. IR (CHCl3): 
3288, 2900, 1608, 1248, 1177, 857, 746, 699 cm-1. ESI-HRMS calcd for C17H22NO2 (M + H+): 
272.1645. Found: 272.1637. 
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(S)-N-(1-Hydroxy-3-phenyl-2-propanyl)-N-(4-methoxybenzyl)nitrous amide (87): To a 1000 
mL round bottom flask containing N-p-methoxybenzyl-L-phenylalaninol (23.1 g, 85.1 mmol) 
was added THF (100 mL) and 2M HCl (64.0 mL, 128 mmol) to make a homogeneous solution. 
To the solution was added NaNO2 (5.87 g, 85.1 mmol) in one portion which reacted 
exothermically. The reaction was stirred overnight. At which point the reaction was extracted 
with 200 mL ethyl acetate and the organic layer was washed with aqueous hydrochloric acid (1M 
HCl, 25 mL), brine (25 mL), dried over MgSO4, filtered and solvents removed in vacuo. The 
crude material was then recrystallized to give the title compound as a yellow solid in 88% yield. 
MP: 79-81 ℃. 1H NMR (CDCl3): δ = 3.13 (dd, J = 8.2, 13.8 Hz, 1H), 3.19 (dd, J = 6.9 13.8 Hz, 
1H), 3.80 (s, 3H), 3.96 (d, J = 5.5 Hz, 2H), 4.31-4.36 (m, 1H), 4.41 (d, J = 14.6 Hz, 1H), 4.82 (d, 
14.6 Hz, 1H), 6.80 (d, J = 8.6 Hz, 2H), 6.95 (d, J = 8.6 Hz, 2H), 7.10-7.11 (m, 2H), 7.24-7.30 
(m, 3H). 13C NMR (CDCl3): δ = 37.6, 47.9, 55.3, 64.2, 65.9, 114.2, 126.1, 126.9, 128.7, 129.1, 
129.8, 137.1, 159.3. IR (CHCl3): 3354, 1612, 1448, 1249, 1177, 1138, 837, 732, 701 cm-1.  ESI-
HRMS calcd for C17H20N2NaO3 (M + Na+): 323.1366. Found: 323.1357. 
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(S)-2-(1-(4-Methoxybenzyl)hydrazinyl)-3-phenyl-1-propanol (88): To a 2000 mL flame dried, 
nitrogen purged, three neck round bottom flask fitted with a pressure equalizing addition funnel 
and a water cooled reflux condenser, was added LiAlH4 (5.689 g, 149.9 mmol), and then was added 
THF (500 mL) to give a dark gray suspension. Heat was applied and THF brought to reflux, at 
which point N-nitrosamine (87) (22.5 g, 74.9 mmol) dissolved in THF (100 mL) was poured into 
the LiAlH4-THF mixture dropwise from the addition funnel. The reaction was stirred under reflux 
for 3 hours. By the end, the reaction mixture took the color of pea soup, at which point heat was 
removed and reaction allowed to cool to room temperature. The reaction was quenched with 
dropwise addition of 1M NaOH (100 mL) from addition funnel. Upon addition of NaOH heavy 
precipitate formation occurred. The precipitate was broken into a slurry and allowed to settle, the 
supernatant solution was then decanted to a 1,000 mL round bottom flask and pumped to remove 
most of the THF. The concentrated reaction mixture was reconstituted with 250 mL ethyl acetate 
and 70 mL 1M NaOH and the organic layer was separated, and the aqueous layer was back 
extracted with 100 mL ethyl acetate. The organic layers were combined, washed with 50 mL brine, 
dried with MgSO4, filtered and the solvents removed in vacuo to give the crude β-Hydroxy 
hydrazine which went on to the cyclization step. 
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(S)-5-Benzyl-4-(para-methoxybenzyl)-1,3,4-oxadiazinone (89): Tetrahydrofuran (THF) (20 
mL) was added to the beta-hydoxyl hydrazine (21.124 g, 73.8 mmol) substrate in a flame dried 
nitrogen purged 250 mL round bottomed flask and left to homogenize at room temperature. 
Carbonyldiimidazole (CDI) (12.0 g, 73.8 mmol) was then added to the solution and left stirring 
for 18 hours at room temperature. Thereafter, the solution was subjected to rotary evaporation to 
remove the THF solvent and the resulting viscous oil was diluted with ethyl acetate (80 mL) and 
washed with 1 M HCl (15 mL) and brine solution (15 mL).  The recovered organic layer was 
dried over MgSO4, filtered under gravity and solvents-removed under reduced pressure. The 
crude product was purified by flash column chromatography (hexanes: Ethylacetate, 60:40) to 
yield 8.05 g (35 %) of the title compound as a yellow solid. MP: 111-112 ℃. 1H NMR (CDCl3):  
δ = 2.89 (dd, J = 8.0, 13.9 Hz, 1H), 2.99 (dd, J =  7.4, 13.9 Hz, 1H), 3.17-3.21 (m, 1H), 3.19 (s, 
3H), 3.83 (d, J = 12.8 Hz, 1H), 4.01 (d, J = 12.8 Hz, 1H), 4.17 (dd, J = 2.1, 11.5 Hz, 1H), 4.60 ( 
dd, J = 3.4, 11.5 Hz, 1H), 6.82 (bs, 1H), 6.84 (d, J = 8.7 Hz, 2H), 2H), 7.11 (d, J = 8.7 Hz,  2H), 
7.17 (d, J = 7.6 Hz, 2H), 7.25-7.33 (m, 3H). 13C NMR (CDCl3): δ = 36.2, 55.2, 55.3, 61.7, 64.1, 
114.1, 126.7, 127.4, 128.6, 129.3, 130.2, 137.5, 151.9, 159.4. IR (CHCl3): 3235, 1718, 1242, 
833, 772, 699 cm-1.  ESI-HRMS calcd for C18H20N2NaO3 (M + Na+): 335.1366. Found: 
335.1358. 
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(S)-5-Benzyl-3-trans-crotonyl-4-(para-methoxybenzyl)-1,3,4-oxadiazinone (90): The 
oxadiazinone substrate (4.203 g, 13.46 mmol) was added to a flame dried, nitrogen purged 250 
mL round bottom flask and dissolved in anhydrous dichloromethane (30 mL). To the solution 
was added trans-cinnamic acid (2.390 g, 16.20 mmol), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) (3.110 g, 16.20 mmol), and 4-dimethylaminopyridine (DMAP) catalyst 
(0.330 g, 2.700 mmol) sequentially. The reaction was allowed to stir for 18 hours at room 
temperature, after which it was diluted with dichloromethane (80 mL) and washed with 1 M HCl 
(20 mL), 1M NaOH (20 mL) followed by brine (20 mL) wash. The organic layer thus recovered 
was dried over magnesium sulfate, gravity filtered, and solvent removed under reduced pressure. 
The crude product obtained was purified by flash column chromatography (hexane: ethyl acetate, 
65:35) to yield 4.221 g (71%) of the title compound as a yellow viscous oil. 1H NMR: δ = 2.77 
(dd, J = 6.0, 13.9 Hz, 1H), 2.86 (dd, J = 8.3, 13.9 Hz, 1H), 3.65 (bs, 1H), 3.71 (s, 3H), 3.87 (d, J 
= 12.5 Hz, 1H), 4.11 (d, J = 12.5 Hz, 1H), 4.16 (bs, 1H), 4.68 (dd, J = 6.2, 11.45 Hz, 1H), 6.76 
(d, J = 8.2 Hz, 2H), 7.12 (m, 5H), 7.27-7.32 (m, 4H), 7.41 (bs, 5H), 7.62 (d, J = 14.8, 1H). 13C 
NMR (CDCl3): (one of the aromatic carbons was not observed potentially due to line 
broadening) δ = 37.7, 55.2, 58.2, 61.8, 68.3, 114.1, 117.7, 126.7, 126.9, 128.4, 128.7, 129.2, 
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130.3, 131.1, 134.8, 136.7, 144.9, 150.3, 159.6, 166.5. IR (CHCl3): 1769, 1680, 1615, 831, 756, 
701 cm-1. ESI-HRMS calcd for C27H26N2NaO4 (M + Na+): 465.1785. Found: 465.1778. 
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N3-(3-methylcinnamoyl)-N4-para-methoxybenzyl oxadiazinone (91): To a 1000 mL flame-
dried, nitrogen purged three-neck round bottomed flask was added copper bromide dimethyl 
sulfide complex (5.884 g, 28.62 mmol), tetrahydrofuran (THF) (27 mL, by syringe) and dimethyl 
sulfide solvent (27 mL by syringe), one after the other. The reaction was then cooled to a 
temperature of -78 ℃. in a dry ice/ethanol bath. Methyl magnesium bromide (9.540 mL, 28.62 
mmol) was then carefully added to the solution by syringe and left to stir for 45 minutes at -78 
℃. The acylated heterocycle (4.221 g, 9.540 mmol) was dissolved in THF (30 mL) and then 
added by dropwise addition to the reaction vessel through an addition funnel. The reaction was 
left stirring for 15 hours while it gradually warmed up to room temperature. The reaction was 
then diluted with ethyl acetate (80 mL) and washed with 1M NaOH (20 mL), 1 M HCl (20 mL) 
and brine solution (20 mL). The recovered organic layer was dried with magnesium sulfate, 
filtered under gravity and solvent removed under high vacuum. The crude product obtained was 
purified by flash column chromatography (Hexane: ethyl acetate, 75:25) to yield 0.4291 g (9.8%) 
of the titled compound as a colorless oil: Significant peak broadening was observed in the 1H 
NMR analysis of this compound, hence, no further analysis was conducted on it.  
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N-Isopropyl-L-phenylalaninol (94c): A 1,000 mL round bottom flask was flame dried and 
nitrogen purged. L-Phenyl alaninol (15.1 g, 99.9 mmol) was added to the flask and dissolved in 
1,2-dichloroethane (350 mL). To the solution was added reagent grade acetone (7.34 mL, 99.9 
mmol), Sodium acetoxy borohydride (NaB(OAc)3H) (29.67 g, 140 mmol) and acetic acid (6 
mL), sequentially and stirred for about 22 hours at room temperature. The product was extracted 
with 6M NaOH (10 mL) and washed with brine. The organic product was dried over MgSO4, 
filtered under gravity and solvents-removed under reduced pressure to yield 8.43 g (44 %) of the 
target compound as a yellow oil. MP: 52-53 ℃. 1H NMR (CDCl3): δ = 0.96 (d, J = 6.2 Hz, 3H), 
1.02 (d, J = 6.2 Hz, 3H), 2.69 (dd, J = 7.2, 13.6 Hz, 1H),  2.75 (dd, J = 6.5, 13.5 Hz, 1H) 2.85 
(sept, J = 6.2 Hz, 1H), 2.94-2.99 (m, 1H), 3.22 (dd, J = 5.9, 10.4 Hz, 1H), 3.54 (dd, J = 4.1, 10.4 
Hz, 1H), 7.15-7.17 (m, 2H), 7.20-7.23 (m, 1H), 7.28-7.31 (m, 2H). 13C NMR (CDCl3): δ = 23.4, 
38.5, 46.0, 57.3, 63.0, 126.4, 128.5, 129.2, 138.5. IR (neat): 2964, 1479, 1039 cm-1. ESI-HRMS 
calcd for C12H21NO (M + H+): 194.1539. Found: 194.1540. 
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(S)-2-(N-Isopropyl-N-nitroso-amino)-3-phenyl-1-propanol (94d): To the N-isopropyl-L-
phenylalaninol (8.43g, 43.6 mmol) starting material in a 1,000 mL round bottomed flask was 
added sodium nitrite (NaNO2) (4.00 g, 58.0 mmol), 3M HCl (22 mL) and tetrahydrofuran (THF) 
(50 mL) and stirred for 18 hours at room temperature. The reaction was diluted with ethyl acetate 
(150 mL) and washed with brine. The organic product was dried over MgSO4, filtered under 
gravity and solvents-removed under reduced pressure to yield 9.15 g (94 %) of the target N-
isopropyl-N4-nitroso-L-phenylalaninol. Only the major isomer is described: 1H NMR (CDCl3): δ 
= 0.77 (d, J = 6.8 Hz, 3H), 1.12 (d, J = 6.8 Hz, 3H), 3.22 (dd, J = 8.0, 13.7 Hz, 1H), 3.33 (dd, J = 
7.1, 13.7 Hz, 1H), 3.78 (dd, J = 3.9, 11.8 Hz, 1H), 3.90 (dd, J = 6.7, 11.8 Hz, 1H) 4.14-4.25 (m, 
1H), 4.37 (bs, 1H), 5.05 (sept, J =  6.8 Hz, 1H), 7.17-7.27 (m, 3H), 7.30-7.34 (m, 2H). IR 
(CHCl3): 3411, 3027, 1601, 1454, 1172, 744, 701 cm-1. ESI-HRMS calcd for C12H18N2O2: 
222.1368. Found: 222.1371. 
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(S)-2-(N-Amino-N-Isopropyl)amino-3-phenyl-1-propanol (95): To the N-isopropyl-N-nitroso-
L-phenylalaninol (9.150 g, 41.16 mmol) starting material in a 1,000 mL round bottomed flask was 
added methanol (83 mL) and heated under reflux until temperature rises up to 50℃. The reaction 
was heated at 50℃ for five minutes, aqueous NaOH (1M, 412 mL, 412 mmol) was then added. 
This was followed with the addition of formamidine sulfinic acid (22.25 g, 205.8 mmol) Still 
maintaining the temperature, and stirred for 5 hours. The product was extracted three times with 
dichloromethane (50 mL each). The resulting organic layers were combined and washed with brine 
(20 mL). The organic product was dried over MgSO4, filtered under gravity and solvents-removed 
under reduced pressure to yield 7.226 g (84 %) of the target hydrazine which was initially an oil 
but turned a white solid upon refrigeration. MP: 59-61 ℃. 1H NMR (CDCl3): δ = 1.13 (d, J = 6.3 
Hz, 3H), 1.17 (d, J = 6.3 Hz, 3H), 2.74 (dd, J = 10.3, 13.1 Hz 1H), 2.83 (dd, J = 3.9, 13.1 Hz, 1H), 
2.94 (sept, J = 6.3, 12.6 Hz, 1H), 3.05-3.10 (m, 1H), 3.53-3.58 (m, 2H), 7.17-7.21 (m, 3H), 7.26-
7.29 (m, 2H).  13C NMR (CDCl3): δ = 19.8, 20.9, 30.0, 55.3, 63.1, 126.1, 128.1, 129.2, 139.5. 
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 (S)-5-Benzyl-4-Isopropyl-1,3,4-oxadiazinone (94): Tetrahydrofuran (THF) (90 mL) was added 
to the N4-Isopropyl hydrazine (7.23 g, 34.7 mmol) starting material in a nitrogen purged 1 L 
round bottomed flask and left to homogenize at room temperature. Carbonyl diimidazole (CDI) 
(5.91 g, 36.5 mmol) was then added and left to stir for 18 hours at room temperature. The 
solution was subjected to rotary evaporation to remove the THF solvent and the resulting viscous 
oil was diluted with dichloromethane (120 mL) and washed with 1 M HCl (20 mL) and brine (20 
mL).  The recovered organic layer was dried over MgSO4, filtered under gravity and solvents-
removed under reduced pressure. The crude product was purified by flash column 
chromatography (hexanes: ethyl acetate, 50:50) to yield 6.28 g (77 %) of the N4-
isopropyloxadiazinone target as a light-yellow solid. MP: 90-91 ℃. 1H NMR (CDCl3): δ = 1.02 
(d, J = 6.2 Hz, 3H), 1.18 (d, J = 6.2 Hz, 3H) 2.84 (dd, J = 8.7, 13.9 Hz, 1H), 2.95 (dd, J = 6.6, 
13.9 Hz, 1H) 3.02 (sxt, J = 6.2, 12.4 Hz, 1H), 3.30-3.33 (m, 1H), 4.08 (dd, J = 1.2, 11.5 Hz, 1H), 
4.45 (dd, J = 3.5, 11.5 Hz, 1H) 6.84 (s, 1H), 7.21-7.25 (m, 3H), 7.29-7.32 (m,2H). 13C NMR 
(CDCl3): δ = 20.3, 20.4, 36.9, 53.1, 55.9, 64.3, 126.6, 128.6, 129.3, 138.0, 152.7. IR (CCl4): 
3514, 1702, 1093, 754 cm-1. ESI-HRMS calcd for C13H18N2NaO2 (M + Na+): 257.1260. Found: 
257.1252. 
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(S)-5-Benzyl-3-trans-cinnamoyl-4-isopropyl-1,3,4-oxadiazinone (96): To a flame-dried 
nitrogen-purged 500 mL round bottom flask was added the oxadiazinone substrate (3.360 g, 
14.34mmol) which was dissolved in anhydrous dichloromethane (80.00 mL). To the solution 
was added trans-cinnamic acid (2.550 g, 17.21 mmol), 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) (3.300 g, 17.21 mmol), and 4-dimethylaminopyridine (DMAP) catalyst 
(0.440 g, 3.585 mmol) sequentially. The reaction was allowed to stir for 18 hours at room 
temperature, after which it was diluted with dichloromethane (80 mL) and washed with 1 M HCl 
(20 mL), 1M NaOH (20 mL) followed by brine (20 mL) wash. The organic layer thus recovered 
was dried over magnesium sulfate, gravity filtered, and solvent removed under reduced pressure. 
The crude product obtained was purified by flash column chromatography (hexane: ethyl acetate, 
75:25) to yield 1.564 g (30%) of the title compound as a yellow oil: IR (neat): 1780, 1674, 1623, 
1285, 1226, 733, 702 cm-1. The acylated product thus obtained was taken through the conjugate 
addition reaction without further analysis. 
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(S)-5-Benzyl-4-isopropyl-3-(3’-phenylbutanoyl)-1,3,4-oxadiazinone (98): To a 100 mL flame 
dried, nitrogen purged three-neck round bottomed flask was added copper bromide dimethyl 
sulfide complex (0.722 g, 3.51 mmol), tetrahydrofuran (THF) (4 mL, by syringe) and dimethyl 
sulfide solvent (4 mL, by syringe), one after the other. The reaction was then cooled to a 
temperature of -78 ℃ in a dry ice/ethanol bath. Methyl magnesium bromide (1.17 mL, 3.51 
mmol) was then carefully added to the solution by syringe and left to stir for 45 minutes at -78 
℃. The acylated heterocycle (0.426 g, 1.17 mmol) was dissolved in THF (4 mL) and then added 
by dropwise addition to the reaction vessel via an addition funnel. The reaction was left stirring 
for 15 hours while it gradually warmed up to room temperature. The reaction was then diluted 
with ethyl acetate (80 mL) and washed with 1M NaOH (20 mL), 1 M HCl (20 mL) and brine 
solution (20 mL). The recovered organic layer was dried with magnesium sulfate, filtered under 
gravity and solvent removed under high vacuum. The crude product obtained was purified by 
flash column chromatography (hexanes: ethyl acetate, 85:15) to yield 0.211 g (47%) of the titled 
compound as a colorless oil: 1H NMR (CDCl3): δ = 0.96 (app. t,  J = 5.9 Hz, 6H), 1.36 (d, J =  
7.0 Hz, 3H), 2.09 (dd, J = 7.8, 13.6 Hz, 1H), 2.47 (dd, J = 6.5, 13.6 Hz, 1H), 2.90-2.97 (m, 2H), 
3.14-3.28 (m, 2H), 3.36-3.45 (m, 2H), 4.15 (dd, J = 7.0, 11.4 Hz, 1H), 7.15-7.31 (m, 10H). 13C 
NMR (CDCl3): δ = 19.6, 20.2, 22.3, 37.3, 39.1, 43.6, 56.9, 57.6, 68.1, 126.6, 126.8, 127.2, 128.5, 
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128.6, 129.3, 137.0, 145.8, 154.0, 172.0. IR (neat): 1789, 1731, 1604, 1289, 1218, 701, 667 cm-1. 
ESI-HRMS calcd for C23H28N2NaO3 (M + Na+): 403.1992. Found: 403.1984. 
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(S)-5-Benzyl-3-trans-crotonyl-4-isopropyl-1,3,4-oxadiazinone (97): To a flame-dried 
nitrogen-purged 250 mL round bottom flask was added the oxadiazinone substrate (1.50 g, 6.40 
mmol) which was dissolved in anhydrous dichloromethane (32.0 mL). To the solution was added 
the sodium hydride (0.310 g, 12.80 mmol). The reaction was allowed to stir for 10 minutes and 
the crotonyl chloride (0.64 mL, 6.7 mmol) was then added. The reaction was left stirring for 18 
hours at room temperature, after which it was diluted with dichloromethane (50 mL) and washed 
with 1 M HCl (20 mL) and brine (20 mL). The organic layer thus recovered was dried over 
magnesium sulfate, gravity filtered, and solvent removed under reduced pressure. The title 
compound was isolated in a yield of 0.345 g (18%) after purification by flash column 
chromatography (hexanes: ethyl acetate, 75:25). 1H NMR (CDCl3): δ = 1.06 (d,  J = 6.3 Hz, 6H), 
1.95 (dd, J =  1.7, 6.9 Hz, 3H), 2.63 (dd, J = 7.8, 13.7 Hz, 1H), 2.91 (dd, J = 6.7, 13.7 Hz, 1H), 
3.11 (p, J = 6.2 Hz, 1H), 3.65 (p, J = 7.3 Hz, 1H), 3.90 (dd, J = 7.7, 11.6 Hz, 1H), 4.40 (dd, J = 
6.9, 11.6 Hz, 1H) 6.80 (dq, J = 1.6, 15.2 Hz, 1H), 7.16 (dq, J = 6.9, 15.2 Hz, 1H), 7.20-7.23 (m, 
2H), 7.25-7.26 (m, 1H), 7.30-7.33 (m, 2H). 
 
 
 
 
116 
 
 
 
(S)-5-Benzyl-4-isopropyl-3-(3’-phenylbutanoyl)-1,3,4-oxadiazinone (99): To a 100 mL flame 
dried, nitrogen purged three-neck round bottomed flask was added copper bromide dimethyl 
sulfide complex (0.703 g, 3.42 mmol), tetrahydrofuran (THF) (4 mL) by syringe and dimethyl 
sulfide solvent (4 mL) by syringe, one after the other. The reaction was then cooled to a 
temperature of -78 ℃ in a dry ice/ethanol bath. Phenylmagnesium bromide (1.14 mL, 3.42 
mmol) was then carefully added to the solution by syringe and left to stir for 45 minutes at -78 
℃. The substrate (97) (0.345 g, 1.14 mmol) was dissolved in THF (4 mL) and then added by 
dropwise addition to the reaction vessel via an addition funnel. The reaction was left stirring for 
15 hours while it gradually warmed up to room temperature. The reaction was then diluted with 
ethyl acetate (80 mL) and washed with 1M NaOH (20 mL), 1 M HCl (20 mL) and brine solution 
(20 mL). The recovered organic layer was dried with magnesium sulfate and filtered under 
gravity followed by the removal of the solvent under high vacuum. The crude product obtained 
was purified by flash column chromatography (hexanes: ethyl acetate, 85:15) to yield 0.306 g 
(70%) of the titled compound as a yellow oil. 1H NMR (CDCl3): δ = 0.96 (app. t,  J = 5.8 Hz, 
6H), 1.36 (d, J = 7.0 Hz, 3H), 2.09 (dd, J = 7.8, 13.5 Hz, 1H), 2.47 (dd, J = 6.4, 13.5 Hz, 1H), 
2.89-3.03 (m, 2H), 3.14-3.28 (m, 2H), 3.36-3.69 (m, 2H), 4.15 (dd, J = 7.0, 11.5 Hz, 1H), 7.22-
7.26 (m, 3H), 7.27-7.30 (m, 3H). 13C NMR (CDCl3): δ = 19.6, 20.3, 21.8, 35.9, 39.1, 43.5, 57.2, 
57.8, 68.0, 126.4, 126.9, 127.1, 128.5, 128.7, 129.2, 136.8, 145.9, 152.9, 172.5. IR (neat): 1786, 
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1724, 1604, 1218, 759, 701 cm-1.  ESI-HRMS calcd for C23H28N2NaO3 (M + Na+): 403.1992. 
Found: 403.1982. 
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Benzophenone imine of phenylalaninol (112): To a 1,000 mL, flame dried, nitrogen purged 
round bottom flask was added anhydrous dichloromethane (250 mL), Benzophenone imine (11.7 
mL, 69.4 mmol) and L-Phenyl alaninol (10.0 g, 66.1 mmol) sequentially, and left to stir for 24 
hours at room temperature. The reaction was then washed with brine (20 mL), dried over 
MgSO4, filtered under gravity and solvents-removed under high vacuum. The target 
benzophenone imine of phenylalaninol was isolated as a yellow solid which was recrystallized 
with ethyl acetate (30 mL) and hexane (2 mL). The pure yellow crystals were recovered by 
vacuum filtration and washed with hexanes and air-dried at room temperature. First and second 
seeds were obtained which yielded a total amount of 20.12 g (97 %) of the title compound as a 
white solid: MP: 121-124 ℃; 1H NMR (CDCl3) : δ = 2.13 (s, 1H), 2.84 (dq, J = 5.4, 7.8 Hz, 2H), 
3.66-3.71 (m, 2H), 3.77-3.91 (m, 1H), 6.64 (d, J = 7.1 Hz, 2H) 6.94-6.96 (m, 2H), 7.12-7.20 (m, 
3H), 7.26-7.39 (m, 6H), 7.55-7.62 (m, 2H). 13C NMR (CDCl3): δ = 39.1, 39.8, 59.6, 65.5, 66.2, 
70.5, 100.0, 125.8, 126.0, 126.3, 126.5, 127.4, 127.6, 127.8, 128.1, 128.2, 128.3, 128.6, 128.9, 
129.8, 130.1, 136.7, 138.6, 138.9, 139.7, 144.6, 169.8.  IR (CHCl3): 3232, 1620, 1294, 732, 700 
cm-1. ESI-HRMS calcd for C23H28N2NaO3 (M + Na+): 338.1515. Found: 338.1505. 
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L-N-diphenylmethyl phenylalaninol (113) : To a 250 mL flame dried, nitrogen purged round 
bottom flask was added Benzophenone imine of phenylalaninol (4.00 g, 12.7 mmol), 
tetrahydrofuran (THF) (20 mL), methanol (20 mL) and sodium borohydride (NaBH4) (0.72 g, 
19.0 mmol) sequentially, and left to stir for 1 hour at room temperature, after which the solution 
was placed on rotary evaporator to remove the methanol. The concentrated solution was then 
diluted with dichloromethane (80 mL) and washed with 1 M NaOH (20 mL) and brine (20 mL). 
The organic layer was dried over MgSO4, filtered under gravity and solvents-removed under 
high vacuum to yield 3.89 g (97 %) of the title compound as a colorless viscous oil: 1H NMR 
(CDCl3): δ = 2.74 (dd, J = 6.0, 12.7 Hz, 1H), 2.82-2.91 (m, 2H), 3.34 (dd, J = 4.5, 10.7 Hz, 1H),  
3.60 (dd, J = 3.4, 10.7 Hz, 1H) 4.92 (s, 1H), 7.07-7.14 (m, 4H), 7.17-7.25 (m, 5H), 7.27-7.33 (m, 
6H). 13C NMR (CDCl3): 38.4, 57.5, 63.1, 64.1, 126.4, 127.1, 127.17, 127.2, 127.4, 128.1, 128.6, 
129.3, 129.8, 138.5, 143.58, 143.59.   IR (CHCl3): 3328, 1600, 1030, 745, 700 cm-1. 
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N- N4-diphenylmethyl-N4-nitroso-L-phenyl-alaninol. (114): To the N4-isopropyl-L-phenyl-
alaninol (0.953 g, 3.00 mmol) starting material in a 1 L round bottomed flask was added Sodium 
nitrite (NaNO2) (4.00 g, 58.0 mmol), 3M HCl (22 mL) and tetrahydrofuran (THF) (50 mL) and 
stirred for 18 hours at room temperature. The reaction was diluted with ethylacetate (150 mL) 
and washed with brine. The organic product was dried over MgSO4, filtered under gravity and 
solvents-removed under reduced pressure to yield 9.15 g (94 %) of the titled compound as a 
yellow solid: 87-90 ℃. 1H NMR (CDCl3): δ = 2.84 (dd, J = 4.9, 13.3 Hz, 1H), 3.23 (dd, J = 10.2, 
13.3 Hz, 1H),  3.87 (dd, J = 5.2, 12.2 Hz, 1H) 3.96 (dd, J = 3.2, 12.2 Hz, 1H), 4.06-4.13 (m, 1H), 
6.40 (s, 1H), 6.81-6.83 (m, 2H), 7.10-7.38 (m,13H). 13C NMR (CDCl3): (mixture of 
diastereomers), δ = 33.9, 38.8, 61.4, 63.7, 69.6, 76.8, 77.1, 77.4, 126.8, 126.9, 128.00, 128.05, 
128.1, 128.2, 128.5, 128.6, 128.7, 128.73, 128.8, 128.83, 128.9, 129.1, 129.3,129.9, 136.6, 137.1, 
137.2, 138.9, 139.1;  IR (CHCl3): 3432, 3065, 1603, 1454, 1141, 733, 701 cm-1. ESI-HRMS 
calcd for C22H22N2NaO2 (M + Na+): 369.1579. Found: 369.1570. 
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APPENDIX B: SELECTED NMR SPECTRA 
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500 MHz 1H NMR spectrum of compound 34 
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100 MHz 13C NMR spectrum of compound 34 
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500 MHz 1H NMR spectrum of compound 43 
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125 MHz 13C NMR spectrum of compound 43 
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500 MHz 1H NMR spectrum of compound 59 
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100 MHz 13C NMR spectrum of compound 59 
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500 MHz 1H NMR spectrum of compound 60a 
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125 MHz 13C NMR spectrum of compound 60a 
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500 MHz 1H NMR spectrum of compound 70 
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100 MHz 13C NMR spectrum of compound 70 
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500 MHz 1H NMR spectrum of compound 71 
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125 MHz 13C NMR spectrum of compound 71 with line broadening 
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500 MHz 1H NMR spectrum of compound 72 
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135 
 
100 MHz 13C NMR spectrum of compound 72 with line broadening 
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500 MHz 1H NMR spectrum of compound 78 
 
137 
 
125 MHz 13C NMR spectrum of compound 78 
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500 MHz 1H NMR spectrum of compound 81 
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100 MHz 13C NMR spectrum of compound 81 
 
140 
 
500 MHz 1H NMR spectrum of compound 80 
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100 MHz 13C NMR spectrum of compound 80 
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500 MHz 1H NMR spectrum of compound 82 
 
143 
 
100 MHz 13C NMR spectrum of compound 82 
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500 MHz 1H NMR spectrum of compound 84 
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100 MHz 13C NMR spectrum of compound 84 
  
146 
 
500 MHz 1H NMR spectrum of compound 86 
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125 MHz 13C NMR spectrum of compound 86 
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500 MHz 1H NMR spectrum of compound 87 
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100 MHz 13C NMR spectrum of compound 87 
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500 MHz 1H NMR spectrum of compound 89 
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100 MHz 13C NMR spectrum of compound 89 
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500 MHz 1H NMR spectrum of compound 90 
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125 MHz 13C NMR spectrum of compound 90 with line broadening 
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500 MHz 1H NMR spectrum of compound 94c 
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125 MHz 13C NMR spectrum of compound 94c 
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500 MHz 1H NMR spectrum of compound 94d 
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500 MHz 1H NMR spectrum of compound 95 
 
158 
 
100 MHz 13C NMR spectrum of compound 95 
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500 MHz 1H NMR spectrum of compound 94 
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125 MHz 13C NMR spectrum of compound 94 
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500 MHz 1H NMR spectrum of compound 97 
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500 MHz 1H NMR spectrum of compound 98 
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163 
 
100 MHz 13C NMR spectrum of compound 98 
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500 MHz 1H NMR spectrum of compound 99 
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100 MHz 13C NMR spectrum of compound 99 
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500 MHz 1H NMR spectrum of compound 112 
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100 MHz 13C NMR spectrum of compound 112 
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500 MHz 1H NMR spectrum of compound 113 
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100 MHz 13C NMR spectrum of compound 113 
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500 MHz 1H NMR spectrum of compound 114 
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100 MHz 13C NMR spectrum of compound 114 
 
